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Abstract 
Introduction: There is great long term concern over the adverse cardiotoxic effects of 
radiation therapy (RT) treatment particularly in left-sided breast cancer (BC) patients 
(Chapman et al 2008). There is currently an urgent need to find a more specific, sensitive 
and clinically valid biomarker which can be used for the earlier detection of radiation induced 
heart disease (RIHD).  MicroRNAs (miRNAs) have appeared as ideal candidate biomarkers 
for early stage RIHD diagnosis due to their non-invasive, fluid-, tissue-, organ- and disease 
specific nature. To date there is no study which focuses upon the utility of previously 
recognised cardiovascular disease linked miRNAs as biomarkers for RIHD and specifically in 
the context of left-sided breast irradiation.  The aim of this work was to thus evaluate 
whether miRNAs which have been previously linked to cardiac damage are differentially 
expressed in BC patients treated for left-sided RT, and if they could provide clues of 
cardiotoxic change earlier and with higher specificity and sensitivity than traditional heart 
imaging and circulation protein based biomarkers.  
Method: This study recruited samples from a larger research study which focused on the 
utility of Cardiac Magnetic Resonance (CMR) imaging in the detection of RIHD at an earlier 
stage in low-radiation dose treated left sided BC women at Oxford University Hospital NHS 
Foundation Trust. A total of 15 low-dose radiation treated left-sided BC women from the 
larger study were recruited to this current study. Total miRNA was isolated from 15 BC 
patients receiving left-side radiotherapy at timepoints: A (baseline pre-radiotherapy), B (24-
72h post radiotherapy), C (3 months post radiotherapy) and D (6 months post-radiotherapy). 
Mean dose to the whole heart ranged from 0.6–2.8 Gray of radiation. Real time PCR was 
performed using TaqMan microRNA assays for microRNAs linked to cardiotoxicity (miR-1, -
27a, -133a, -133b, -29b, -30a, -505, -144, -208a, -451 and -125a) using sno U6 as internal 
reference. The ΔΔCT calculation method was used. Students t-test was performed to 
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analyse the data when time point A was compared to D alone (p<0.05). A one-way ANOVA 
was also conducted to explore individual relationships between A, B, C and D. 
Results:None of the 15 BC patients were noted to have suffered myocardial damage from 
CMR imaging, BNP or troponin results. Significant miRNA expression changes were 
observed when utilising students t-test comparing time point A and D (n=8-15) for: miR-1 
(increased nearly 3-fold,  p=0.0378), miR-27a (decreased nearly 4-fold, P=0.0464), miR-451 
(decreased more than 2-fold, P= 0.0321), and miR-125a (increased more than 3-fold, 
P=0.0098).miR-144 was also found to be upregulated from A (n=10) to C (n=7) (P≤0.01) and 
decreased back to baseline levels from C (n=7) to D (n=12) (P≤0.0001). Other statistically 
significant relationships include a more than 3-fold increase in the levels of miR-1 from time 
point B  to D (p=0.002) and C to D (p=0.003).  miR-125 levels also increased by more than 
2-fold between time points B to D (p=0.031). miR-144a levels increased by more than 465-
fold from time point A to C (p<0.01) and then decreased by more than 1600 fold from time 
point C to D (p<0.0001). miR-133b levels  were found to significantly decrease by more than 
40-fold between A (n=10) to B (n=8) (p=0.015). The expression levels of miR-133a, miR-
29b, miR-30a and miR-505 were not altered 6 months post-radiotherapy. The expression of 
miR-208a was undetectable at all time points in this study (n=7-13). 
Conclusion:This study has shown that miR-1, miR-27a, miR-125 and miR-451 were altered 
from the pre-radiation to the 6 month post-radiation stage in left sided RT BC patients, 
whereas imaging and circulation cardiac injury protein biomarkers did not change at all. In 
addition it was also observed that miR-144 and miR-133b shows a differential regulation 
pattern in response to RT.  As none of the patients within this study developed clinically 
diagnosed cardiotoxicity as a result of radiation, the link between RIHD as a cause of these 
expressional changes cannot be established. However this study does highlight that miRNAs 
warrant further investigation in larger patient cohorts for potential as early stage biomarkers 






AMI: Acute myocardial infarction  
BC: Breast Cancer 
BNP: Brain Natriuretic Peptide 
CMR: Cardiac Magnetic Resonance 
CAD: Coronary Artery Disease 
cTnI: Cardiac troponin I  
cTnT: Cardiac troponin  
EF: Ejection Fraction 
Gy: Gray 
HF: Heart Failure 
IHD: Ischaemic Heart Disease 
miR: microRNA 
miRNAs:microRNAs 
MI: Myocardial Infarction  
NICE: National Institute of Clinical Excellence 
qRT-PCR: quantitative reverse transcription-polymerase chain reaction 
RT: Radiation Therapy 
RIHD: Radiation Induced Heart Disease 
SPECT: Single photon emission computed tomography 
TIC: Therapy Induced cardiotoxicity 








Section 1. Introduction 
1.1 Breast Cancer Incidence and Radiotherapy 
 
More than one million cases of breast cancer (BC) are diagnosed each year worldwide 
(Perry et al 2008). It is the most commonly occurring neoplasm in women in both high 
resource and low resource settings and accounts for over one-fifth of the estimated annual 
4.7 million cancer diagnosis in females (Beiki et al 2012). It is also the second most common 
tumour after lung cancer in both sexes (Ferlay et al 2001). Furthermore, it is the primary 
cause of cancer death amongst women globally and is responsible for more than 500,000 
deaths each year worldwide (Siegel et al 2016).  
 
Radiation Therapy (RT) is a critical component of the multidisciplinary management of 
invasive BC. It is estimated that 50% of patients will receive RT at some stage of their 
clinical treatment. In appropriately selected patients, RT not only improves local control, by 
reducing morbidity and chances of local recurrence but also improves survival by preventing 
seeding and reseeding growth of distant metastases from persistent reservoirs of 
locoregional disease (Jagsi et al 2013). Timothy et al. showed that adjuvant RT statistically 
significantly reduced the risk of mortality (odds ratio = 0.83, 95% confidence interval [CI] 
=0.74 to 0.94; p=.04) (Timothy et al 2003). 
 
It is possible to summarise and group the stages of BC into early stage various different 
stages based upon the size of the tumour and whether the cancer has spread. Stage I is a 
tumour no larger than 2cm and has not spread to lymph nodes. Locally advanced stage 
disease encompasses stage II and III whereby the tumour is between 2-5cm and may have 
spread to lymph nodes under the arm or surrounding breast tissue. Advanced or metastatic 
stage disease encompasses stage IV whereby tumour has spread to other organs in the 
body for examples lungs, liver or bone.  Stages I, IIA, IIIB, are considered ‘early stage’ 
breast cancer and refer to cancers that may have spread to nearby lymph nodes but have 
not metastasized. It is therefore not surprising that treatment options for early stage are 
11 
 
different to those for advanced stage disease (Kirova et al 2010). Approximately of the 
55,000 new cases of BC diagnosed each year in the UK, 60% of patients are diagnosed with 
early stage BC, 33% patients are diagnosed at the locally advanced stage and 5% of 
patients are diagnosed with advanced or metastatic BC (McNeely et al 2006). Approximately 
98% of patients will survive for 5 years if they have early stage BC. Around 74% of patients 
with locally advanced BC will survive for 5 years and roughly 20% of BC patients with 
advanced or metastatic disease will survive for 5 years. (Joshi et al 2007).Unsurprisingly, 
restoring the quality of life in patients with early stage breast cancer remains a clinical priority 
due to their increased chances of living longer.  
 
The four main applications of RT in the primary treatment of BC are in treating early stage 
invasive disease, locally advanced BC and as postmastectomy therapy (Taghian et al 1999). 
The primary treatment of BC patients with early stage BC is usually breast-conserving 
surgery followed by RT as adjuvant therapy, where RT is used to destroy any remaining 
mutated cells that remain in the breast or armpit area post-surgery (Jacob et al 2016).  Lim 
et al. who conducted a prospective study of lumphectomy alone without RT in early stage 
BC patients found at 7 year follow up the local recurrence rate to be unacceptably high at 
23%. We can thus conclude that RT given after breast conservative surgery among patients, 
at moderate or high risk of dying from cancer, has favourable effects on survival. In fact 
multiple clinical trials have also shown a substantial risk of local recurrence if RT is omitted 
after breast conserving surgery (Cutuli et al 2009; Whelan et al 2010). 
1.2 Radiation Induced Heart Disease (RIHD) 
 
Radiation-induced heart disease is a term used to refer to the spectrum of cardiac 
pathologies, including myocardial fibrosis and cardiomyopathy, coronary artery disease, 
valvular disease, pericardial disease, and arrhythmias which are a result of radiation to the 





Unfortunately, while breast radiotherapy improves overall survival, there is strong evidence 
that due to incidental exposure of the heart to RT adverse effects from radiation exposure 
can lead to development of heart disease, in particular left-sided RT, which can progress to 
heart failure and death (Madan et al 2015). Patients who receive post-mastectomy RT for left 
sided breast cancer are 2-3 times at a higher risk of developing cardiovascular disease as 
compared to right sided BC patients. (Madan et al 2015). This is because in left sided BC, 
the apex and anterior wall of the heart typically receive the highest dose of radiation and 
consequently the left anterior descending and distal diagonal regions are most prominently 
involved due to the national positioning of the heart which pre-disposes the heart to 
developing clinically significant cardiac abnormalities (Donnellan et al 2016). Approximately 
51% of patients have left sided BC, 46% of patients have right sided breast cancer, and 3% 
of patients have simultaneous bilateral malignancy (Amer et al 2014). As left sided BC 
patients receive higher RT doses and that too specifically to the heart, this study focused 
upon left sided BC patients as miRNA signals would be hypothetically stronger in these 
patients. No statistical significance has been noted in survival between left and right sided 
breast cancer as a result of the cancer itself although as discussed above RIHD is of greater 
risk in left sided BC patients contributing to risk of mortality (Amer et al 2014).  
 
Considering RT pathogenesis, RT can cause both acute and chronic effects on the heart as 
shown below in Figure 1. Radiation-related cardiac disease  is known to induce pathological 
changes including endothelial damage causing perfusion abnormalities, myocardial oedema, 





Figure 1: Demonstration of the pathophysiology of RIHD induced injury and end-clinical 
manifestations. Radiation to the heart can induce both acute and chronic effects by 
implication of Tumour Necrosis Factor and interleukins resulting in an immune response 
which causes damage to vessels, conductive tissue, myocardium and pericardium (Taunk et 
al 2015). 
 
Various alternative approaches to minimise the burden of treatment have been sought due 
the increased chance or mortality due to Radiation Induced Heart Disease (RIHD).  This 
includes hypofractionation of radiation treatment which involves the use of larger daily doses 
of radiation and decreases the total number of fractions that must be administered.  The UK 
Standardisation of Breast Radiotherapy Trial B compared contemporary 50 Gray (Gy) of RT 
in 25 fractions and 40 Gy in 15 fractions over 3 weeks in 2125 BC women. They found that 
there was a significantly lower rates of adverse effects in the group who received the 
Some materials have been removed from this thesis due to Third Party Copyright. The unabridged version of the thesis can be 
viewed at the Lanchester Library, Coventry University. 
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accelerated hypofractionated RT regime (40 Gy in 15 fractions over 3 weeks)(Kim et al 
2016). Combined with the fact that radiation doses received by the heart are generally lower 
from contemporary RT then older RT techniques, it is likely that the cardiac injury risk from 
modern day RT treatments is lower than the past (Taylor et al 2007). However, RT treated 
BC patient hearts still receives a mean radiation dose of between 1 and 5 Gy on average 
during treatment of the left-sided BC and there is evidence that even this low dose poses a 
significant risk (Carr et al 2005; Shimizu et al 2010;, Darby et al 2013).   
 
Cardiac damage has been shown to be correlated with the heart-absorbed dose of RT. 
Darby et al. who conducted a population based case control study of major coronary events 
in BC patients demonstrated that rates of major coronary events such as myocardial 
infarction (MI), coronary revascularisation, or death from ischaemic heart disease increased 
linearly with a mean dose to the heart by 7.4% per increase in Gy with no apparent 
threshold. They found the increase in risk to start within the first 5 years after completed RT 
and continued into the third decade after RT. Interestingly, the proportional increase in risk in 
the rate of major coronary events per Gy was similar in women with and women without 
cardiac risk factors at the time of RT. Furthermore, they also found the percentage increases 
in the rate of major coronary events per Gy of radiation according to the number of years 
since radiation exposure were as follows: 0 to 4 years, 16.3%; 5 to 9 years, 15.5%; 10 to 19 
years, 1.2%; and 20 or more years, 8.2% (Darby et al 2013). 
 
BC RT of the heart has been shown to be associated with long-term cardiotoxicity, such as 
heart failure (HF) and myocardial infarction (MI) and finally cardiovascular death. More than 
10 years after RT the  relative risk is in  the range of 1.2 to 3.5 times by comparing left-
breast treated patients who are at a higher risk to those that are unexposed or treated on the 




Cardiotoxicity is described as either subclinical myocardial injury (development of 
asymptomatic cardiac abnormalities) or clinical toxicity (objective cardiac damage).  More 
specifically, clinically, cardiac toxicity can be defined as one of the following:  
1) Reduction of LVEF, either global or specific in the intraventricular septum; 2) symptoms or 
signs associated with heart failure (HF); 3) reduction in LVEF from baseline ≤ to 5% to 
<55%  in the presence of signs or symptoms  of HF (Seidman et al 2002). It is these three 
criteria which were used to assess patients for the presence of cardiotoxicity.  
 
Risk factors for RIHD include radiation dose >30-35 Gy, dose/fraction more than 2 Gy, large 
volume of irradiated heart, younger age at exposure, longer time since exposure, use of 
cytotoxic chemotherapy, endocrine therapy or trastuzumab. Other risk factors for RIHD 
include diabetes, hypertension, dyslipidemias, obesity and smoking (Bovelli et al 2010).  
 
1.2.2 Current Prevention and Management of Breast Cancer 
 
The European Society of Medical Oncology has issued guidelines for the prevention, 
diagnosis and management for cardiovascular disease development associated with cancer 
therapy. Briefly the guidelines call for aggressive cardiac risk-factor risk modification through 
weight-loss, exercise, blood pressure control and smoking cessation, in addition to early 
identification of RIHD. The current approach to RIDH diagnosis includes imaging and 
measurement of circulating cardiac injury protein biomarkers. 
 
1.2.2.1 Diagnosis of Breast Cancer usingImaging 
 
Baseline comprehensive transthoracic echocardiography (TTE) is advocated in all patients 
before starting RT to detect anomalies. Beyond this, an annual history and physical 
examination, paying close attention to the signs and symptoms of cardiopulmonary disease 




In asymptomatic patients, screening TTE at 10 years after RT is recommended. In patients 
with no pre-existing cardiac disease, surveillance TTE is recommended should be at 5-year 
intervals thereafter. In asymptomatic high-risk patients, those who have undergone anterior 
or left sided RT and have at least one risk factor for RIHD, initial screening TTE is 
recommended 5 years post RT. If this initial examination is negative, stress CMR is 
recommended. 
 
The imaging modality that has been used most frequently to study RIHD following BC is 
single photon emission computer tomography (SPECT) nuclear myocardial perfusion 
imaging. More recently tissue Doppler echocardiography has also been used (Erven et al 
2011). However, there is currently no data advocating the use of any of these imaging 
techniques as screening tools (Lancelloti et al 2013).  
1.2.2.2 Diagnosis of Breast Cancer using protein biomarkers 
 
Circulating cardiac injury protein biomarkers can be used in the assessment of myocardial 
injury. Cardiac troponin I (cTnI) is cardiac-muscle-specific, whereas cardiac Troponin T 
(cTnT) is expressed in damaged skeletal muscle (Jaffe et al 2000). It has been found that 
cTnI and cTnT are released into the blood circulation at levels which reflect the extent of 
myocardial injury, therefore they could be said to be specific and sensitive to a certain extent 
(Collinson et al 2005). However cardiac cell injury which does not result in an altered cardiac 
muscle cell membrane disruption may not be associated with increases in serum proteins. 
This is significant as apoptotic signalling can be generated by interaction of ionising radiation 
with cellular membranes (Sharma et al 2004). In addition in cases of altered ion 
homeostasis, valvular diseases and contractile dysfunction, levels of serum troponins may 
not be increased (Collinson et al 2005). In a study of 50 women with BC, no change in 






Brain Natriuretic Peptide (BNP) is a cardiac neuro-hormone which is secreted by the 
ventricular myocardium in response to changes in volume expansion and pressure 
overloading during myocardial stress or HF (Maisel et al 2002). It has been shown that the 
release of BNP is directly correlated with the degree of ventricular wall tension and generally 
BNP secretion correlates with echocardiographic indices of systolic and diastolic dysfunction 
and clinical HF (Sandri et al 2005). However, BNP is not recommended for diagnostic 
screening of therapy-induced cardiotoxicity (TIC) due to poor sensitivity and the fact that 
levels vary significantly based upon the physiological characteristics of the patient, thus 
making it difficult to establish a cut off (Nousianen et al 2002; Daugaard et al 2005).  
 
Hence based on current knowledge, circulating cardiac injury protein biomarkers are not 
recommended for evaluation of radiation-induced cardiotoxicity but remain a useful research 
tool. 
1.2.2.3 RIDH and current diagnostics issues RIHD 
 
The most important issue however remains that subclinical cardiac damage occurs in more 
than 50% of BC patients who undergo RT (Darby et al 2013). Subclinical cardiac injury can 
be defined as development of asymptomatic cardiac abnormalities in previously healthy 
cancer survivors (Carr et al 2005). As can be seen from the above clinical guidelines, 
patients are not reviewed until 5-10 years post RT when damage to the heart is often chronic 
and irreversible (Lancelloti et al 2013). There is currently no active monitoring either of 
patients either for cardiac abnormalities post RT unless they complain of cardiac-related 
symptoms by which time the cardiac damage has progressed significantly. 
 
Nilsson et al demonstrated a four- to sevenfold increased risk of stenosis in the coronary 
arteries post left sided BC irradiation with 70% of abnormalities occurring in the left anterior 
descending coronary artery (Nillson et al 2012). 
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Marks et al (2005) found that in 114 left-sided BC patients treated with RT 42% developed 
new perfusion defects. Up to 70-90% of patients with significant mediastinal radiation 
exposure can develop pericardial disease (Veinot et al 1996). Furthermore nearly 20% of 
these patients may have initially have had effusions (Stewart et al 1984).   Patients who 
receive at least 32 Gy of radiation to the heart then upto 81% of patients have been 
discovered to be suffering from valvular dysfunction and fibrosis (Brosius et al 1981).  The 
aortic and mitral valves are more commonly involved than the tricuspid and pulmonary 
valves.  Conduction abnormalities arise due to micro vascular damage which lead to cardiac 
myocyte conduction abnormalities or direct damage to critical structures such as sinoatrial or 
atrio-ventricular nodes. In 200 BC survivors, ECG results showed that the risk of developing 
conduction abnormalities increased from 19% to 45% at 6 months post RT, T-wave changes 
were post predominant in this group. The risk remained at 45% 10 year post treatment with 
the pathology changing to fewer T wave abnormalities but more ST depression and ectopic 
beats (Strender et al 1986). However unlike other RIHD types, cardiac conduction 
abnormalities are largely reversible and the peri-myocardial damage indicated is functionally 
insignificant.  
 
Subclinical myocardial injury is progressive and can develop into HF over time. Therefore, 
early identification of RIHD is key to minimising the harmful side effects of cancer therapy 
and would allow clinicians to personalise the programme of cancer therapy for patient’s there 
improving survival 
 
Furthermore, it is imperative to recognise that RIHD may be detectable within a matter of 
days to months post RT. It has been found that amongst 200 BC survivors, a significant 
percentage had conduction abnormalities at both 6 months and 10 years after treatment 
(Taunk et al 2015). Pericarditis may develop over a period ranging from a few months to few 
years with a typical presentation at 12 months (Madan et al 2015). Importantly asymptomatic 
pericardial perfusion is the most common mode of presentation for the development of 
19 
 
delayed pericarditis (Zhuang et al 2017). Perfusion defects of the heart have been shown to 
be evident in 50% to 63% of patients 6 to 24 months after RT (Darby et al 2013). Gayed  et 
al have further supported these findings by demonstrating 27%, 29%, 38%, 42% incidence 
of myocardial perfusion abnormalities in asymptomatic patients with BC at 6, 12, 18 and 24 
months after RT, respectively (Gayed et al 2009).  
 
Due to the limited sensitivity and specificity as well as high cost of currently used techniques 
which may be used to detect RIHD, there is an urgent need for the development of a new 
non-invasive and cost effective diagnostic biomarker that can be used for the earlier 
detection of RIHD.  
 
1.3 miRNA biogenesis and function 
 
Small non-coding RNAs (∼ 22 nucleotides) known as miRNAs have a critical role in the 
regulation of mRNA or protein levels through mRNA degradation or attenuation of mRNA 
translation (Bartel et al 2004). One miRNA can target several mRNAs, and one mRNA can 
be regulated by several different miRNAs. Up until now more than 2000 mature unique 
miRNAs have been identified in humans (https://www.mirbase.org) and it is estimated that at 
least 60% of all mammalian mRNAs are regulated by miRNAs (Friedman et al 2009).  
 
Figure 2demonstrates the process of miRNA maturation and function. The miRNA gene is 
transcribed under the control of RNA polymerase II (though some can be generated by RNA 
polymerase III) to generate a primary microRNA (pri-miRNA) precursor molecule that 
undergoes nuclear cleavage by the RNase III enzymes Drosha in the nuclear and Dicer in 
the cytosol to form a precursor microRNA (pre-mRNA).  The pre-miRNA is cleaved in the 
cytoplasm to create a microRNA duplex (miRNA:miRNA*, passenger strand is indicated by 
asterix) containing the mature miRNA. The duplex unwinds and the guide strand of this 
duplex associates with RNA-induced silencing complex (RISC) whereas the passenger 
strand of this miRNA duplex is either degraded or utilised as functional miRNA by the same 
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cell or exported to another cell (O’Toole et al 2016).  The miRNA base-pairs with target 
mRNA to direct gene silencing via mRNA cleavage or translation based upon the level of 





























Figure 2: Diagram of miRNA maturation and function (see section 1.3 for a detailed 
description)(Friedman et al 2009). 
 
Both the miRNA sequences and the miRNA-processing are evolutionary conserved, 
indicating the critically important role of miRNAs in biological function (Bartel et al 2004; 
Zhao et al 2007). 
Some materials have been removed from this thesis due to Third Party Copyright. The 




1.3.1 miRNAs are involved in biological processes including cardiovascular 
disease development 
 
miRNAs participate in many cellular processes, such as apoptosis (Xu et al., 2007), fat 
metabolism (Xu et al 2007), cell differentiation (Chang et al 2008), tumourigenesis (Zhao et 
al 2007), cardiogenesis and angiogenesis (Zhao et al 2007). 
In the cardiovascular system, miRNAs have been shown to be critical regulators of 
development and physiology.  They control basic functions in virtually all cell types relevant 
to the cardiovascular system (such as endothelial cells, cardiac muscle, smooth muscle, 
inflammatory cells, and fibroblasts) and therefore are directly involved in the pathophysiology 
of many cardiovascular diseases. As a result of their role in disease, they are being studied 
for exploitation in diagnostics, prognostics and therapeutics.  
 
Interestingly, the promoters of RNA polymerase II often containing toxicologically significant 
enhancer regions, indicating that miRNAs play a role in response to cellular stresses and 
gene changes following exposure to toxic substances. It has already been shown that 
ionising radiation induces oxidative stress hence altering expression of miRNAs (Friedman 
et al 2010). 
 
1.3.2 miRNAs as ideal biomarker candidates 
 
An ideal diagnostic biomarker has to fulfil a number of criteria, such as accessibility through 
non-invasive methods, high-specificity indicating myocardial origin, a reliable indication of 
early detection of the disease before clinical symptoms appear, high-sensitivity to changes in 
pathology: disease progression or therapeutic response, and they must be robust and 
translatable (Vasan et al 2006). As with all healthcare services, clinical effectiveness has to 
be balanced with cost and it essential for an ideal biomarker to be cost effective and also 
offer high-throughput testing such that the test can be performed simply and quickly and 




miRNAs resemble the characteristics of an ideal biomarker incredibly well. Advantageously, 
miRNA sequences are stable in a variety of different body fluids, such as blood plasma and 
serum (Mitchell et al 2008), urine (Dimov et al 224), saliva (Michael et al 2010), amniotic fluid 
and pleural fluid (Gilad et al 2008). In 2008 it was discovered that miRNAs are also present 
in blood where they were found in plasma, erythrocytes, platelets and nucleated blood cells 
(Chen et al 2008). Stability of miRNAs is due to protection from degradation by 
ribonucleases, RNA-binding proteins and lipid vehicles (Valadi et al 2007).  Importantly as 
discussed below miRNAs are tissue/fluid, disease type and stage specific (Etheridge et al 
2011). Furthermore, it is viable to detect homogenous miRNA by quantitative PCR and next 
generation sequencing. All of the above discussed qualities make miRNAs thus a very 
attractive diagnostic biomarker (Mitchell et al 2008).  
 
The introduction of a reliable early-stage miRNA biomarker for RIHD would allow clinicians 
to introduce preventative adjunct therapy to protect the heart at an earlier stage, thus limiting 
and stopping heart disease progression. Furthermore, clinicians could tailor anti-cancer 
therapy regimes for BC patients in a more personalised manner reducing risk of 
cardiotoxicity. This would undoubtedly improve the quality of life and increase the survival of 
BC patients.   
1.3.3 Fluid- and tissue- specificity of cardiac miRNAs 
 
Plasma miRNAs were found to be remarkably stable even under conditions as harsh as 
boiling, low or high pH, long storage at room temperature and multiple freeze thaw cycles 
(Mitchell et al 2008).  
 
miR-208a and miR-499 are expressed specifically in heart tissue (van et al 2007; Adachi et 
al 2010), whereas miR-1 and miR-133 have been found in injured skeletal muscle (van et al 
2009; Chen et al 2006).  These miRNAs which are highly expressed in cardiac muscle have 
been noted to be involved with heart development and myocyte differentiation (Zhao et al 




It has also been noted that miRNAs are differentially expressed depending upon on the 
various compartments of the organ. For example it has been noted that the arteries of the 
heart express a different miRNA profile than the heart, suggesting a cell-type-specific miRNA 
expression profile.  Cardiac muscle cells express miR-30c, miR-1 and miR-133 (Lagos-
Quintana et al 2002). Coronary atrial smooth muscle cells express miR-1, miR-133, miR-
125a, miR-145 and miR-143 (Schmidt et al 2007). In contrast coronary atrial endothelial cells 
express miR-126, which is responsible for controlling angiogenic sprouting of aortic arch 
vessels (Nicoli et al 2010). 
 
The presence of miRNAs in microparticles has intrigued the idea that circulating miRNAs 
could have a role in cell to cell communication. This would further suggest that miRNAs are 
selectively targeted for secretion in one cell and taken up by a distant, target cell, possibly in 
order to regulate gene expression. Subsequent studies have revealed that miRNAs may 
indeed function as mediators of cell to cell communication (Zhang et al 2010).  
miRNAs can be readily accessed in body fluids and based on the above it is unsurprising 
that in HF similar responses in miRNA levels in the circulation and in myocardial tissue have 
been observed. For example Tijsenet al. (2010).found higher levels of miR-423-5p in both 
circulation of the heart failure patients and in post mortem samples of patients suffering from 
dilated cardiomyopathy (Tijsen et al 2010).  However it is certain that potential miRNA 
targets need to be further scrutinized for their true clinical value with respect to 
cardiovascular disease, especially as there is much debate over which targets may actually 
be of use. For example the group of Vogel et al. (2013) found that miR-423-5p was not 
significantly dysregulated in whole peripheral blood of HF patients with reduced ejection 
fraction. It should be noted that Tijsen et al. (2010) measured miRNAs from plasma samples 
whilst Vogel et al. (2013) assessed whole peripheral blood samples. The advantage of 
analysing miRNAs in whole blood peripheral samples is that tissue-related miRNAs can be 




1.3.4 miRNAs are cardiac development stage specific 
 
Functional miRNA studies reported that a variety of miRNAs play a role in pathogenic 
mechanisms leading to heart failure, such as remodelling, hypertrophy, apoptosis, and 
hypoxia (Tijsen et al 2012). Furthermore, in response to the progression of heart failure, 
miRNAs were shown to behave in a dynamic and stage-specific way. For example, 
decreased levels of miRNAs (including miR-1 and miR-133a) were found before 
development of disease (Ji et al ) while an increasing number of miRNAs exhibited a 
dysregulated and mainly up-regulated pattern in the later stages towards end-stage heart 
failure (Mitchel et al 2008). Others demonstrated that the aetiology of heart failure 
(ischaemic, aortic stenosis, or idiopathic cardiomyopathy) was associated with differentially 
expressed miRNA patterns (Ji et al 2007). Thus, compelling evidence suggests that miRNAs 
play an active role in the onset and progression of heart failure.  
 
1.3.5 miRNAs in the developing and healthy adult heart 
 
miRNAs have been identified in cardiac tissue at all stages of development and those highly 
expressed in the foetal heart include miR-21, miR-29a, miR-129, miR-210, miR-211, miR-
320, miR-423, and let-7c (Thum et al 2007). The critical role of miRNAs during embryonic 
and postnatal cardiac development has been established in the literature. 
In the healthy adult heart it has been established that a huge number of miRNAs which are 
highly expressed in non-diseased cardiac tissue, are likely to play a key role in both normal 
cardiac maintenance and disease development. These include miR-1, miR-16, miR-27b, 
miR-30d, miR-126, miR-133, miR-143, miR-208 and the let-7 family(Bartel et al 2004; Thum 
et al 2008). 
1.3.6 Cardiac disease specific miRNA expression 
 
The next section focuses upon key cardiac injury specific miRNAs, which are involved in 
specific heart diseases.  
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1.3.6.1 miRNAs in Acute Myocardial Infarction (AMI) patients 
 
It has been demonstrated that measuring miR-1 in plasma is a good approach for blood-
based detection of AMI in patient as they correlated well with infarct size (Ai et al 2010; 
Cheng et al 2010). Also increased miR-1 is well correlated with abnormal electrical activation 
in AMI patients, and after treatment plasma miR-1 recovered to normal value (Taurino  et al 
2010).  
 
A miRNA microarray study demonstrated that mIR-1, miR-133a, miR-499 and miR-208a 
were elevated in the plasma from 33 AMI patients compared to as well as healthy subjects, 
patients with non-AMI coronary heart disease or patients with other cardiovascular diseases. 
This study demonstrates a specific nature of miRNA to differentiate between different 
subtypes of cardiovascular disease. Notably, within 4 h of the onset of symptoms, miR-208a 
was easily detectable in AMI patients, but remained undetectably in non-AMI patients (Wang 
et al 2010). However the study by D’Alessandra et al showed miR-208a to not be detectable 
at all in AMI patients. This could have been due to two reasons. Firstly D’Alessandra et al 
collected samples approximately 9 hours post AMI onset whereas Wang et al collected them 
sooner at 4 hours post onset. All miRNAs have different times at which they peak depending 
on the type of initiation or response they are involved in with respect to myocardial injury and 
repair. For example it is known that miR-208a levels peak within the first 2 hours post injury 
which could explain why the study by D’Alessandra et al failed to detect any miRNA. 
Furthermore, the methods used to detect miRNA between the study of D’Alessandra and 
Wang et al differed. Thus when interpreting miRNA findings the timing of sample collection 
and method utilised appear to be crtitical factors in establishing differential regulation 
patterns and must be critiqued to truly establish the clinical utility of candidate markers.  
Also, Adachi et al pointed out that very low levels of mIR-208a and mIR-208b  exist in 
human hearts thus deeming it as an unsuitable marker of myocardial injury in humans due to 
it not being particularly involved in normal human heart and development. Therefore it is 
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important to only recognise and take those miRNA candidates forward in research where 
possible which have an organ- disease and tissue specific origin.   
 
Devaux and colleagues reported that a panel of four miRNAs (miR-16, miR-27a, miR-101, 
miR-150) improved the prediction of left ventricle contractility six months after AMI, in a 
multivariable model that included NT-proBNP, an established biomarker of heart failure 
(Devaux et al 2013). These findings built upon their previous demonstration that reduced 
levels of miR-150 levels were associated with increased left ventricle remodelling after ST 
segment elevation myocardial infarction and herald promise in the use of miRNAs, or panels 
of miRNAs, as diagnostic and prognostic predictors of heart failure. 
1.3.6.2 miRNAs in Heart Failure (HF)patients 
 
Plasma levels of heart-muscle enriched miR-1, miR-133a, miR-208b, mIR-499; fibrosis 
associated miR-21, miR-29b, and leukocyte associated miR-146, miR-155, miR-223 have all 
been tested as candidate biomarkers of HF (Corsten et al 2010). This study demonstrated 
that in humans, diverse conditions of myocardial damage are associated with striking 
perturbations of plasma levels of cardiac miR-208b and miR-499 in acute HF (minimal), viral 
myocarditis (marked) and AMI (extensive).  An intriguing observation was the correlation of 
miR-133a plasma levels with BNP in asymptomatic patients with diastolic dysfunction, which 
was not observed in acute HF patients. Corsten et al supported these findings by showing 
that expression of miR-208b, miR-499, miR-1 and miR-133a in acute HF patients. They 
found that the expression of all four of these myocardial injury miRNAs were elevated in 
acute HF patients (Corsten et al 2010). However in interpreting the significance of these 
findings it must be remembered that this study utilised incredibly small N numbers thus 
reducing the statistical power of the findings. This study recruited only 32 AMI patients, 39 
patients with diastolic dysfunction and 33 acute heart failure patients which is not a 
substantial enough sample size to ascertain strong statistical significance.  Furthermore 
acute heart failure can be the result of a huge range of cardiac abnormalities including 
valvular complications, arrhythmias, and coronary artery disease. It was unclear from this 
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study the exact causes  of the congestive heart failure in the patients the study focused upon 
and certainly larger studies focusing one each cause of heart failure would be necessary to 
be confident that these miRNAs do indeed play a role in acute heart failure.  
 
1.3.6.3 miRNAs in Coronary Artery Disease (CAD) patients 
 
Plasma miRNA are also differentially regulated in CAD patients. Analysis in patients with 
stable CAD revealed that myocardial-injury-specific miR-133 and miR-208a were up 
regulated, whereas inflammation associated miR-155 and smooth muscle enriched miR-145 
were down regulated (Chen et al 2006).  It has been shown that circulating miR-155 and 
miR-145 are also decreased in cases of CAD and could act as diagnostic biomarkers of 
coronary artery disease (Bartel et al 2004) 
 
1.3.6.4 miRNA in Hypertension and Atherosclerosis patients 
 
Numerous studies have been conducted to detect circulating miRNAs implicated in 
hypertension patients. The results indicated that the plasma miR-505 was significantly 
elevated in essential hypertensive patients, thus circulating miR-505 maybe a circulating 
biomarker for hypertension (Ji et al 2007).  
 
A recent study also identified several novel up-regulated miRNAs (miR-23b, miR-130a, and 
miR-191) and down-regulated miRNAs (miR-451 andmiR-1246) in the circulation of patients 
suffering from pulmonary hypertension (PH) (Wei et al 2013). Another research also found 
that reduced miR-150 was closely associated with poor survival in pulmonary hypertension 
patients (Rhodes et al 2013). Furthermore, Santovito et al have shown that miR-145 is over-
expressed in atherosclerotic plaques of hypertensive versus normotensive patients 
undergoing carotid endarterectomy, implicating miR-145 as a potentially key regulator of 




1.3.6.5 miRNA in Fibrosis and Arrhythmia 
 
The miR-29 family has been implicated in cardiac fibrosis following a report showing down-
regulation of miR-29 family, miR-29a, miR-29b and miR-29c in the border of human hearts 
during MI. Multiple target genes of the mIR-29 family were identified including extracellular 
membrane proteins, such as collagens, fibrillins, and elastin and it was speculated that 
transforming growth factor (TGF-β) mediated down regulation of miR-29 would enhance 
fibrosis (van Rooji et al 2008). Furthermore, it has been shown that miR-1 levels are 
markedly reduced in atrial tissue of patients with atrial fibrillation compared to those patients 
without (Liao et al 2016). 
 
1.3.7 miRNAs in aiding cardiomyocyte cell survival 
 
It has been noted in the literature that miR-144/451 individually augment cardiomyocyte 
survival which is further improved by over-expression of both of these miRNAs in response 
to ischaemia/reperfusion injury (Zhang et al 2010). 
 
1.3.8 miRNAs in response to cancer therapy induced cardiotoxicity 
 
To date there is no study which focuses upon the utility of miRNAs as a marker for RIHD and 
specifically in the context of left-sided breast irradiated cancer patients.Very few studies 
have looked upon miRNA expression patterns during chemotherapy-induced cardiotoxicity. 
For example, it has been noted that plasma miR-29b and miR-499 are acutely elevated (at 
6-12h) in cases of anthracycline induced cardiotoxicity amongst children and young patients 
with leukaemia (Leger et al 2017). Interestingly here too there was a dose response 
relationships observed with anthracycline dose and markers of cardiac injury. In the plasma 
of 59 BC patients treated with doxorubicin chemotherapy miR-1 was significantly found to be 




1.3.8.1 miRNAs in Breast Cancer 
 
It should be noted that in cancer miRNAs play a role in oncogenesis, metastasis and 
resistance to various therapies and can be classified as oncogenes (oncomirs) or tumour 
suppressor genes (Ahmad et al 2011). Interestingly, it has been noted that miR-155 
promotes proliferation of human breast cancer cells (Zhang et al 2010) 
 
It has also been noted that quantification of certain miRNAs could even be used to predict 
response to radiotherapy. For example low levels of miR-34a rendered BC cells more 
resistant to radiotherapy (Kato et al 2009).  
 
It has even been suggested that microRNAs such as miR-21 and miR-34 are very promising 
new targets for RNA-based therapy in non-invasive and invasive BC (Kaboli et al 2015).  
1.3.9 Application of miRNAs in various disease states 
 
It is important to recognise when assessing the potential clinical value of miRNAs that they 
are not only differentially regulated in myocardial conditions but in a variety of cancers (e.g. 
lung cancers, gastric cancers, oesophageal cancers), viral diseases, immune related 
diseases (e.g. diabetes, multiple sclerosis, diabetes), neurogenerative diseases (for example 
Parkinson’s and Alzheimer’s disease), and therefore have a role in diagnosis and therapy in 
multiple disease states (Li et al 2012).  
 
Interestingly to highlight the utility of miRNA in the diagnosis if neurogenerative disease the 
University of Melbourne Centre of Research, Innovation and Commercialisation have 
developed a blood test for the early detection of Alzheimer’s disease which they are 




1.3.10 Clinical detection of miRNAs 
 
microRNAs can be detected clinically relatively simply in tissues and tissue fluids using 
quantitative reverse transcription-polymerase chain reaction (qRT-PCR).  With technical 
advancements, it is now possible to detect low copy numbers of both the precursor and the 
mature forms of miRNAs with great sensitivity and specificity (Chen et al 2005). With 
technological advancement and increasing interest, novel analytical approaches for profiling 
miRNA expression continue to emerge (Srivastava et al 2013). 
 
1.4 Research Area 
 
We hypothesise that RT will result in a signature of differentially affected cardiac injury 
specific miRNAs and this could potentially be used as a more effective early stage RIHD 
screening tool. The study will assess cardiac injury specific genomic miRNA substances in 
the bloodstream to help identify specific mIRNAs which could be used for the earlier 
identification of RIHD. The long-term goal of this study is to identify a genomic biomarker 
high throughput screening platform to profile sub-clinical myocardial injury and drug-induced 
cardiotoxicity and potential use in evaluating agents used to prevent cytotoxic induced injury. 
1.4.1 Hypothesis 
 
We hypothesise that RT treatment will result in a signature of differentially affected cardiac 
specific miRNAs which could then be exploited to identify RIHD at an earlier stage. 
1.4.2Aim 
 
The work aims to evaluate whether miRNAs which have been previously linked to cardiac 







1. Undertake miRNA assessment for cardiotoxicity in the circulation following RT in left sided 
RT treated patients where risk of cardiotoxic damage is the greatest compared to right-sided 
RT.  
2. Compare miRNA expression profiles in patient over various time points of RT to see 
changes across time. Time points to investigate include Time point A (pre-RT), Time point B 
(24-72h from final fraction of treatment), Time point C (3 months post RT) and Time point D 
(6 months post RT). 
3. Compare the sensitivity and specificity of miRNAs to traditional proteomic biomarkers 



































Section 2. Materials and Methods 
2.1 Ethics Statement 
 
This study was performed in accordance principle of the Declaration of Helskinki as well as 
adhering to the requirements of good clinical practice (GCP). This study has gained the 
relevant ethical approval from each partner institution including Coventry University (CU), 
Oxford University Hospital NHS Foundation Trust (OUH NHS Trust) and Health Research 
Authority (HRA). Written informed consent was obtained from all patients before blood 
sample and imaging collection. 
Ethical Approval Number: OUH NHS Trust and HRA- 09H060483; CU- P46798. Please find 
ethics approval confirmations from Coventry University and OUH NHS Trust attached to the 
front of the thesis. 
2.2 Patient Population and Inclusion criteria 
 
This study recruited samples from a larger research study which focused on the utility of 
imaging in the detection of RIHD at an earlier stage in low radiation dose treated left sided 
BC women based on availability of samples across all 4 time points as mentioned in section 
2.4. This larger study was conducted at Oxford University Hospital NHS Foundation Trust.  
This study had previously revealed that CMR imaging was in agreement with troponin and 
BNP findings in that none of the patients had developed RIHD at 6 months post their RT.  A 
total of 15 low-dose radiation treated left-sided BC women from the larger study were 
recruited to this current study. The 15 women whose date and samples were used all had 
had early stage BC or Ductal Carcinoma in Situ post breast-conserving surgery treated with 
low dose left sided RT and had been treated at the Cancer Centre, Oxford University 
Hospital NHS Foundation Trust. These patients were routinely treated in accordance with 
Trust Approved RT Guidelines in line with those recommended by the National Institute of 
Clinical Excellence (NICE 2009) on the Early and locally advanced BC: diagnosis and 




2.2.1 Exclusion Criteria 
 
Women who were <18 or 65> years, adjuvant cytotoxic chemotherapy, previous significant 
heart disease, diabetes, oestrogen receptor positive tumours receiving hormone therapy 
were all excluded from this study. 
2.3 Radiotherapy planning and delivery 
 
The prescribed dose was 40 Gy in 15 fractions, 5 fractions per week, prescribed to a 
normalisation point in the centre of the breast, with 50 Gy in 25 fractions used for exceptional 
cases (women with very large breasts). A boost dose of 10 Gy in 5 daily fractions was given 
where indicated, using electrons of appropriate energy to a clinically defined tumour bed. 
2.4 Blood Sample Collection and Analysis 
 
Blood samples in EDTA tubes would be obtained at each time point A, B. C and D. Where:  
• A = baseline pre-RT 
• B = 24h-72h immediately after first RT Dose 
• C = 3 months post-final fraction of RT 
• D = 6 months post-final fraction of RT 
EDTA blood samples were then processed for plasma within 1 hour of collection. Blood was 
centrifuged at 3000g for 20 minutes at 10°C, followed by further centrifugation of the 
supernatant at 15000g for 10 minutes at 10°C to remove the cell debris. Plasma samples 
were then analysed for Troponin and BNP using an Abbott Architect analyzer in the routine 
biochemistry laboratory.  After this the samples were aliquoted into tubes, labelled and 
stored at -80°C in preparation for miRNA analysis. MRI scans would also be performed 
where routine measurements and more sophisticated measures on MRI provided 
information on the structural integrity of the heart and assessment of ventricular function 
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including (i.e. Ejection fraction (EF), stroke volume, left ventricular end systolic volume and 
left ventricular end diastolic volume). 
Information that was available to this study included amount of radiation dose, Troponin 
value, BNP value, stroke volume, ejection fraction at each visit. Unfortunately data 
surrounding more intricate measures of cardiac magnetic resonance from the larger study as 
well as details of co-morbidities were not available to this study.  However all medical 
histories were reviewed by clinicians to ensure appropriate inclusion utilising the patients’ 
medical records and therefore the inclusion and exclusion criteria strictly applies to this 
patient cohort.  
 
2.5 List of Consumables and Suppliers 
 
RNaseZAP (Ambion), Qiagen RNeasy Mini Kit inclQIAzol(Qiagen), MS2 RNA (Roche) 
Chloroform (Ambion), microRNA primer assays (Thermofisher Scientific), Applied 
Biosystems TaqMan microRNA Reverse Transcription Kit- (Thermofisher Scientific), 
TaqMan Universal PCR Mastermix (Thermofisher Scientific). 
 
2.6 miRNA extraction from plasma 
 
Total RNA was extracted from 1000 ml of plasma with the miRNeasy Mini Kit (Qiagen) and 
the modified Exiqon protocol explained below which includes the addition of MS2 RNA 
(Roche), a carrier RNA that ensures the highest and also the most consistent yield of RNA in 
the samples. All plastic consumables handling the plasma samples were RNase free and 
tips were in addition with filters. The samples were handled with gloves sprayed with 
RNaseZAP (Ambion) in order to reduce the spread of RNase. A volume of 0.5 ml plasma 
was defrosted for each patient in time points A, B, C and D totalling a sample volume of 
0.5ml. Samples were transferred into 2.0 ml tubes appropriately labelled and spun at 1000 g 
for 5 minutes at 4°C in order to remove the cell debris.  Plasma was carefully transferred into 
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fresh 2 ml tubes avoiding the debris. To each plasma sample 5 µl of MS2 RNA and 1ml of 
Qiazol was added. This mixture was then vortexed and allowed to stand at room 
temperature for 5 minutes.  To each sample 500 µl of chloroform was added. During the 
uptake of chloroform, the pipette was fully compressed upon entering the acid phenol: 
Chloroform solution (piercing through the phenol layer which is used to neutralize and 
suppress the action of the chloroform) producing bubbles visible to the eye and where 
uptake of the solution could be visualised. The samples were once again vortexed and 
allowed to stand for 2 minutes at room temperature after which point the samples were spun 
down at 14000 RPM for 20 minutes at 4°C. At this stage centrifugation resulted in the 
formation of distinct layers within the sample; the upper phase containing RNA, and the 
interphase and lower phase.  Only the upper aqueous containing the RNA was carefully 
extracted and transferred to fresh RNAase free collection tubes leaving a small layer on the 
interphase line to prevent the phases being disturbed and therefore contaminating the 
isolated RNA.  In the proportion of 50µl upper phase to 1150µl ethanol was added to each 
sample. RNeasy Mini Spin columns were labelled with patient number and time point. A total 
of 750µl of lysate/ethanol mixture and successive applications from the same patient sample 
and time point were made to the filter until all the sample was used up.  Once complete, 700 
µl of RWT was solution was added to the filter cartridge and centrifuged followed by three-
times500µl RPE wash solution. Samples were centrifuged at 14000 RPM for 1 minute at 4 
°C and the flow-through was discarded until all the lysate/ethanol/wash buffer mixture was 
washed through the filter. Following the last wash the filter cartridges were transferred back 
into fresh collection tubes and centrifuged at 14000 RPM for 1 minute at 4 °C in order to 
remove the residual fluid from the filter. After the filter had dried for 1 minute at RT 50µl of 
nuclease free water from the Qiagen Kit was used and added to the centre of the 
membrane. This was incubated for 1 minute and then spun at 14000 RPM for 1 minute at 4 
°C in order to recover the RNA.  The resulting eluate was stored at -20°C in preparation for 







The extracted RNA concentration and purification was determined via the ND 1000 
Spectrophotometer (Thermo Scientific USA). RNA-40 sample type was selected prior to 
analysis on the analyser, and the analyser was blanked prior to each reading using 1 µl of 
RNAse free water on the Nanodrop pedestal and run in order to calibrate the 
spectrophotometer. Sample purity was observed via the A260/280 and A260/230 ratios.  
2.8 Reverse Transcription PCR (RT-PCR) 
 
A total of 1800ng of miRNA was reverse transcribed into cDNA for U6, miR-1, miR- 27a, 
miR-133a, miR-133b, miR-29b, miR-30a,  miR-144, miR-451, miR-505 and miR-208a via the 
microRNA Reverse Transcription Kit. These specific miRNAs were chosen for investigation 
due to their involvement in both normal cardiac development as well as changes in 
expression patterns in both acute and chronic cardiac disease states ranging from AMI to 
heart failure as discussed in the introduction. The miRNAs were also chosen due to varying 
times of expressional changes post cardiac injury ranging from hours to months in order to 
capture changes in our own sample population which ranged from 24 hours post radiation up 
to 6 months. The reverse transcriptase mastermix was produced as shown in Table 1. 
Table 1: Volume (µl) for reverse-transcriptase master mix constituents needed for 1 
reaction. 




Buffer  7.5 
Specific primer sets 1.5 each 




Samples were diluted with 75 µl of H2O after RT-PCR.  
The reverse transcriptase PCR reaction was performed using the master cycler gradient via 
the following set up; 16°C for 30 minutes, 42°C for 30 minutes  and 85°C for 5 minutes. This 
reaction resulted in the production of cDNA.  
2.9 Real Time PCR 
Upon preparation of the cDNA, the real time PCR reaction was performed as shown in Table 
2. 
Table 2: Volume (µl) for real-time PCR master mix constituents needed for 1 reaction. 
Real Time PCR 
mastermix 
For 1 reaction (µl) 
Taqman 10 




14.5µl of the Real Time Mastermix (Taqman, Primer and H2O) mixture would be aliquoted 
into each well and 5.5µl of the prepared cDNA was added.  
The cDNA samples were carefully loaded in duplicates with the pipette tips carefully 
changed in order to prevent any contamination. Once prepared in the configuration shown 
below the PCR plates were gently centrifuged for 1000 RPM for 1 minute at 4 °C to ensure 
all the sample content migrated to the bottom of the well. 
 
The real time PCR process was utilised using 1800ng of starting cDNA alongside the 
specific primer sets and a standard Taqman Universal PCR mastermix (as per the 
manufacturer’s instructions) on the CFX Connect Real Time PCR system (BioRad, USA). 
The real time PCR sequence detection software CFX manager (Applied Biosystems USA) 
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was used to monitor the amplification of DNA by means of real time optics and imaging via 
the binding of SYBR green fluorescent dye to double stranded DNA.  
The real time PCR thermal cycling reaction was programmed to run at 50 °C for 2 minutes, 
95 °C for 10 minutes and then 40 cycles of 95°C for 15 seconds followed by 60°C for 1 
minute.  
The cycle threshold values for all patient time points were compared to U6 snRNA which 
was used as an internalised reference.  
 
2.10 Statistical Analysis 
 
CT data obtained from the above was initially entered and analysed using Microsoft Excel 
whereby the mean, average, standard derivation (SD), Standard error of mean (SEM) was 
calculated . Analysis of the miRNA data was performed using the comparative ΔΔCT 
method. Relative quantities of miRNAs were calculated using the CT values obtained via 
Real-Time PCR analysis of target miRNAs: miR- 1, miR-27a, miR-133a, miR-133b, miR- 
29b, miR-30a, miR-208a, miR-505, miR-144, miR-451 and miR-505)  in relation to the U6 
snRNA values in the sample via the following formula: 
X0/R0=2CTR-CTX 
Where X0 is the original amount of target miRNA, R0 is considered the original amount of 
U6 snRNA, CTR is the CT value for U6 snRNA, and CTX is the CT value for the target 
miRNA. The average miRNA sample ratio values was calculated for each time point. Any 
samples which were 5-fold above or below the mean were discarded. A prospective 
statistical power calculation revealed that a larger N number was needed of at least 30 
samples per time point. A total of 15 subjects were recruited into this study and generally 
N numbers between 7-12 were included once outliers had been discarded miRNA 
analysis. Though the N numbers in this study did not meet the requirement for statistical 
power the main reason for this was that the study relied upon samples being available 
across all 4 time points from the larger CMR imaging study which unfortunately  was the 
case for only 15 patients.  
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The miRNA ratio values produced from the formula were further analysed graphically 
using GraphPad PRISM. GraphPad Prism was initially used to construct graphs of 
average changes in expression levels of miRNA over the 4 time points (A, B, C and D). 
One-way ANOVA test was used in GraphPad prism based upon the above ratios to 
determine significant expression differences between points: A-B, A-C, A-D, B-C and C-D 
where significant differences P<0.05. In addition a student’s T-test was used to compare A 
and D (RT treatment start and end-points), where significant differences were considered 
























Section 3: Results 
3.1 Experimental Design Summary 
 
A total of 15, left sided RT treated subjects were taken through the experimental design 




Figure 3: Demonstration of the experimental process. Each of the 15 BC patients recruited 
into the study were taken through the above experimental design process. 
 
Recruitment of 15 BC Patients , Clinical History 
obtained
CMRimages obtained for  each  patients at each time 
point, on the same visit bloods taken for BNP and 
troponin analysis (N=15) 
miRNA EXtraction for each patient and time point 
(N=15, Samples=60)
RT-PCR (N=15, Samples=59)
Real Time PCR (N=15, Samples =59)
Statistical Analysis of changes in expression Levels of 
between each time points and time point start (A) 
and finish (D) using  T-Test and analysis of changes 




3.2 Characteristics of the 15 BC patients 
 
The mean age of patients was 56.8 years with the lowest age being 41 and the highest age 
being 62. Cardiac risk factors within some but not all of these patients included smoking 
(both current and previous), hypertension, hypercholesterolaemia, and a family history of 
previous cardiac disease.  
 
3.3 Cardiac Radiation Dosimetry 
 
The mean dose to the whole heart, left ventricle, and left coronary artery was 1.4 Gy, 2.0 Gy, 
and 6.6 Gy, respectively. The maximum dose given to the whole heart, left ventricle and left 
coronary artery was 32.89 Gy, 30.18 Gy, 30.50Gy respectively. 
 
3.4 Troponin and BNP Analysis 
 
All patients has normal levels of Troponin I, below the limit of detection for the assay (<0.04 
µg/L) at all time points as shown in table 3. Any result greater than 0.04µg/L is deemed to be 
indicator of ischaemic heart disease. Even a slight increase is deemed to be clinically 













Table 3: Troponin values for all patients across the 4 different time points A to D. 
There were no significant changes in the expression of Troponin values for any 
patient. 
Troponin Levels ( ug/L) over time points 
 A B C D 
1 <0.2 <0.2 <0.2 <0.04 
2 <0.2 <0.2 <0.04 <0.04 
3 <0.04 <0.04  <0.04 
4 <0.04 <0.04 <0.04 <0.04 
5 <0.04 <0.04 <0.04 <0.04 
6 <0.04 <0.04 <0.04 <0.04 
7 <0.04 <0.04 <0.04 <0.04 
8 <0.04 <0.04 <0.04 <0.04 
9 <0.04 <0.04 <0.04 <0.04 
10 <0.04 <0.04 <0.04 <0.04 
11 <0.04 <0.04 <0.04 <0.04 
12 <0.04 <0.04 <0.04 <0.04 
13 <0.04 <0.04 <0.04 <0.04 
14 <0.04 <0.04 <0.04 <0.04 
15 <0.04 <0.04 <0.04 <0.04 
 
All measures of BNP were also normal (0.6-28.9 pmol/L) as shown in Table 4. Transient 
changes in BNP were considered clinically insignificant.  BNP levels greater than 236 pmol/L 
are considered to be an indicator of HF. Raised levels greater than 47 pmol/L are considered 









Table 4: BNP values across all 4 time points for each individual patient. There were no 
significant changes in BNP levels for any of the patients. 
 
Changes in BNP Levels (pg/ml) 
Patient A B C D Changes 
1 17.0 27.6 33.8 20.1 +3.1 
2 3.5 7 6.4 2.5 -1.0 
3 1.6 2.5   2.6 +1.0 
4 9.3 14.3 12.7 15.6 +6.3 
5 11.4 2.1 4.6 7.5 -3.9 
6 12.8 3.8 9.8 8.8 -4.0 
7 4.6 0.9 2.6 4.1 -0.5 
8 8.2 6.7 3.1 5.5 -2.7 
9 2.1 <0.6 3.8 0.7 -1.4 
10 13.8 2.4 3.8 1.8 -12.0 
11 13.8 4.8 7.5 6.5 -7.3 
12 2.6 4.8 2.7 3.1 +0.5 
13 5.0 4.3 5.2 3.3 -1.7 
14 4.7 5.7 4.2 3.9 -0.8 
15 24.4 12.4 30.6 18.4 -6.0 
 
3.5 Cardiovascular Magnetic Resonance Results 
 
A consultant cardiologist was responsible for reviewing the CMR images who was blinded to 
the study and the dose of RT received by the patients however was informed that the 
patients were part of the research study.  
 
There was no evidence of any change in basic indices of left ventricle function between the 
time points studied. A normal EF of greater than 55% is usually considered as normal. The 
EF readings for all of the patients remained normal across all 4 time points (n=15) as shown 






Table 5: Ejection fraction values for all patients from time points A to D (n=15). There were 
no changes for EF for any of the patients. 
Ejection Fraction (%) 
Patient  A B C D 
Change in EF from onset 
(%) 
1 82 83 81 81 -1 
2 74 74 78 82 +8 
3 73 75 70 78 +5 
4 76 75 75 74 -2 
5 77 79 80 81 +4 
6 81 79 74 79 -2 
7 68 65 64 63 -5 
8 62 66 70 64 +2 
9 79 73 77 75 -4 
10 73 76 74 68 -5 
11 79 72 75 72 -7 
12 75 73 72 75 0 
13 71 72 66 67 4 
14 79 79 76 79 0 





Figure 4: Graphical demonstration of the changes in EF over the course of the 4 time points A to D. All the patients had normal EF readings during 



































































A normal stroke volume is deemed to be between 50ml-100ml /beat (Vella et al 2005). No 
patients had any significant changes in stroke volume post-RT as shown in table 6. 
 
Table 6: Stroke volume (ml/beat) readings for all patients over time points A to D (n=15).  
There were no significant changes in stroke volume for any of the patients from start to the 
end of radiotherapy 
 
Time Points  










1 61 77 79 77 86 
2 52 111 111 116 108 
3 61 78 84 71 87 
4 62 83 79 88 91 
5 60 107 115 116 115 
      
6 58 90 101 93 84 
7 55 93 78 77 71 
8 61 75 80 102 77 
9 61 91 88 95 74 
10 52 105 118 121 87 
11 58 101 83 98 77 
12 57 87 81 67 73 
13 41 86 95 84 82 
14 52 81 91 83 91 
15 61 85 87 66 88 
      
 
3.6 miRNA values and RT-PCR 
 
miRNA purification analysis using Nanodrop Spectrophotometer 
The nanodrop technique is used to quantify the purification quality. Purines and pyrimides in 
nucleid acids usually show a peak absorbance at 260nm whereas proteins and phenolic 
compounds absorb UV light near 280nm. 
The 260/280 ratio specifies the purity of the nucleic acid.The RNA extraction was considered 
pure and free from contamination if this ratio was ~2.0, which is reflected by the 260/280 
ratio. Furthermore, absorbance measured at 230nm is a result of concomitants such as 
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phenol, guanidine and other buffers such as QIAzol. Therefore, the 230/260 ratio is utilised 
as a secondary measure of the nucleic acid purity, and the values obtained for ‘pure’ nucleic 
acid are generally greater than the respective 260/280 ratios with expected values ranging 
generally in the range of ~2.0-2.2. Where the value is appreciably lower than expected, it is 
there that contamination is suspected.  
Initially, 1µl of RNase was free water was pipette onto the measuring pedestal of the ND-100 
Nanodrop to both zero and calibrate the Nanodrop to ensure the analyser was functioning 
and the RNase free water was not contaminated. After which, the miRNA samples were then 
successively pipette onto the Nanodrop ND-100 measuring pedestal following vigorous 
scraping of the surrounding Eppendorf walls of the sample via the pipette tip, dislodging and 
exposing the residual RNA. A spectrophotometric reading was drawn following the sample 
measurement between 2 optic fibres 
3.7 Total RNA 
 
The total RNA (including miRNA) concentration values using Nanodrop spectrophotometer 
ranged from 20.4-268.4 ng/µl. 
The diluted concentrations of the miRNA samples ranged from 6.7-44ng/µl.  
Due to sample insufficiency, the miRNA concentration could not be quantified in sample 
11B. Of the samples that presented protein purity (260/280), all of the samples were 
considered around the acceptable pure range, contrasting with the 260/230 ratio where 
fewer samples were considered free of organic compound contamination.  
A peak of 230nm was seen in most samples. Figure 5, showing sample 32D, demonstrates 
an example of the contamination peak seen at 230nm. Contamination as a result of phenol 


















.Figure 5: Nanodrop profile of sample 32D showing a peak at 230nm. This peak was a 
result of contamination of phenol, guanidine and QIAzol buffer. The red arrow indicates the 
presence of the contamination peak. 
 
The concentration of total RNA and of the diluted miRNA samples retrieved from Nanodrop 
















Contamination peak at 230nm 
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Table 7:  Purity Levels for all samples.Sample purity levels indicate good quality sample 
purity levels however the 260/230 ratio values for each sample do indicate contamination as 









2A 20170307 78.8 1.89 1.08 22.8 21.7 
2B 20170307 60 2.03 1.18 30.0 14.5 
2C 20170307 54.9 2.05 1.5 32.8 11.7 
2D 20170307 268.4 2.11 2.19 6.7 37.8 
7A 20170307 71.1 1.89 1.05 25.3 19.2 
7B 20170307 66.6 2.04 1.75 27.0 17.5 
7C 20170307 47.9 2.05 1.89 37.6 6.9 
7D 20170307 53.1 2.01 1.52 33.9 10.6 
11A 20170307 51.4 2.03 1.95 35.0 9.5 
11B 20170215 20.4 1.56 0.2   
11C 20170222 56.16 1.84 0.51 32.1 12.4 
11D 20170222 63.94 2.1 1.68 28.2 16.3 
12A 20170222 40.89 1.94 0.32 44.0 0.5 
12B 20170222 58.23 2 1.47 30.9 13.6 
12C 20170222 170.15 2.07 2.13 10.6 33.9 
12D 20170222 158.9 2.07 2.06 11.3 33.2 
13A 20170222 129.36 2.06 1.65 13.9 30.6 
13B 20170222 139.68 2.09 2.15 12.9 31.6 
13C 20170222 75.86 2 2.01 23.7 20.8 
13D 20170222 143.01 1.96 2.03 12.6 31.9 
14A 20170222 119.12 2.07 1.93 15.1 29.4 
14B 20170307 48.2 2.03 1.59 37.3 7.2 
14C 20170223 65.76 2.02 1.5 27.4 17.1 
14D 20170223 58.37 2.02 1.58 30.8 13.7 
16A 20170223 62.02 2.04 0.39 29.0 15.5 
16B 20170223 62.34 2.03 1.61 28.9 15.6 
16C 20170223 60.57 2.04 1.77 29.7 14.8 
16D 20170223 63.93 2.07 1.06 28.2 16.3 
20A 20170223 62.34 2.09 1.97 28.9 15.6 
20B 20170223 62.73 2.05 1.66 28.7 15.8 
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20C 20170223 68.29 2.06 1.93 26.4 18.1 
20D 20170223 57.48 2.02 1.46 31.3 13.2 
22A 20170223 65.41 2 1.41 27.5 17.0 
22B 20170223 59.38 2.03 1.59 30.3 14.2 
22C 20170223 61.9 2.01 1.73 29.1 15.4 
22D 20170223 60.58 1.97 1.68 29.7 14.8 
23A 20170223 59.49 2.08 1.57 30.3 14.2 
23B 20170223 95.37 1.8 0.94 18.9 25.6 
23C 20170223 62.11 2.06 1.49 29.0 15.5 
23D 20170223 60.24 1.98 1.29 29.9 14.6 
26A 20170223 61.97 2.05 1.88 29.0 15.5 
26B 20170223 54.95 1.95 1.17 32.8 11.7 
26C 20170223 60.6 2.03 1.54 29.7 14.8 
26D 20170223 58.43 2.03 1.3 30.8 13.7 
29A 20170223 58.08 2.05 1.74 31.0 13.5 
29B 20170223 67.74 1.99 1.24 26.6 17.9 
29C 20170307 61.8 1.98 1.9 29.1 15.4 
29D 20170307 83.4 1.95 0.39 21.6 22.9 
30A 20170307 67.6 2.04 1.68 26.6 17.9 
30B 20170307 98.3 1.81 1.1 18.3 26.2 
30C 20170307 60.9 1.96 0.7 29.6 14.9 
30D 20170307 73 1.91 1.29 24.7 19.8 
31A 20170307 65 2.05 1.37 27.7 16.8 
31B 20170307 66.5 2.01 1.01 27.1 17.4 
31C 20170307 63.7 2 0.8 28.3 16.2 
31D 20170307 54.7 1.99 0.63 32.9 11.6 
32A 20170307 92.3 1.94 1.19 19.5 25.0 
32B 20170307 64.3 2.04 1.99 28.0 16.5 
32C 20170307 56.8 1.97 1.38 31.7 12.8 
32D 20170307 61.1 1.97 0.43 29.5 15.0 
 
 
3.8 Reverse Transcriptase and Real Time PCR analysis 
 
Using the miRNA concentrations and purity readings from Nanodrop, the amount of miRNA 
required for each sample yielding a concentration of 1800ng/µl was calculated. miRNAwas 
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transcribed into cDNA successfully as real time PCR analysis gave CT value readings for all 
samples. 
Determinations of the miRNA concentrations and purity via the Nanodrop spectrophotometer 
aided further calculations in determining the quantity of miRNA required for each sample to 
yield a concentration of 1800 ng/µl (as shown in Table 7 above) cDNA was efficiently 
transcribed using Real Time PCR as shown by the CT values in Table A-E in the appendix. 
miRNA target gene analysis was carried out in duplicate. 
 
The real time PCR data was normalized to U6, the housekeeping gene for miRNA prior to 
analysis which is a crucial quality control aspect during quantification analysis. Each miRNA 
was screened for in each sample at each time point in duplicate (plate design shown in 
Table C, in the Methods and Methodology Section) and corresponded with the respective CT 
value obtained.  Ct values for the majority of duplicate samples were considered consistent 
with one another and therefore reliable, however a few samples differed slightly by 
presenting a narrow variation in values.  
Table 8a-11d shows individual miRNA analysis results for each patient across each time 
point with their subsequent time points, for ease of comparison data is shown divided by 
time point. 
3.9Sample ratio values 
 
Via Excel, the individual ratio values for each individual samples was calculated via the 
formula 
X0/R0=2CTR-CTX 
Where X0 is the original amount of target miRNA, R0 is considered the original amount of 
U6 snRNA, CTR is the CT value for U6 snRNA, and CTX is the CT value for the target 
miRNA. 




Ratio values from Real Time PCR for Time Point against each miRNA for Time Point A are 




Table 8a: Time point A. Calculated ratio values via excel per sample 2-26 with respect to 

























































































































































N 11 11 11 10 11 11 
 
 
Table 8b: Time point A. Calculated ratio values via excel per sample 2-26, with respect to 
their corresponding miR-208a, miR-505, miR-144, miR-451, miR-125 
Target Gene 
Sample  208 * 505 144 451 125 
2   1.765170108   845.0835679 21.63356182 
7 0.628643501 54.65961005 19.155103 36010.00787 2605.493751 
11   1.088061869 0.309215719 692.1016925 84.89814447 
12   0.942072784 0.278699366 1403.823007 89.385408 
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13 0.025030546 0.399069776 0.113793986 892.5995275 21.42685189 
14   0.43706301 0.086716833 294.208214 5.805244287 
16 0.012269831 0.609239471 0.342923995 4422.407306 189.9096845 
20   1.709945406 0.444590375 555.5238985 51.25614367 
22 0.024854293 1.719328712 0.365702829 1338.019851 68.69300181 
23   3.478435074 1.437009055 1346.121573 108.8586718 
26 0.022005977 0.38533163 1.243971105 310.1309026 10.44321003 
Mean 0.142560829 6.108484353 2.377772626 4373.638856 296.1639703 
S.D 0.271778299 16.12842284 5.912652685 10554.22559 767.8074476 
S.E.M 0.12154295 4.862902456 1.86974495 3182.21875 231.5026559 
N 5 11 10 11 11 
 
Table 8c: Time point A.Calculated ratio values via excel per sample 29-32 with respect to 
their corresponding miR-1, miR-27, miR-133a, miR-133b, miR-29b, miR- 30a 
 
Target Gene 
Sample 1 27 133a 133b 29b 30a 
29 0.399585 8.059494 0.769272 0.046392 0.028512 5.404522 
30 0.443932 7.29461 0.77753 0.03622 0.013325 146.2681 
31 0.425146 1.507932 0.357076 0.172154   16.50424 
32 0.130633 4.463368 0.342975 0.023159 0.018542 19.16786 
Mean 0.349824 5.331351 0.561713 0.069481 0.020126 46.83618 
S.D 0.147253 2.981559 0.244527 0.069106 0.007716 66.55537 
S.E.M 0.073627 1.490779 0.122264 0.034553 0.004455 33.27768 
N 4 4 4 4 3 4 
 
Table 8d: Time point A.Calculated ratio values via excel per sample 29-32, with respect 
to their corresponding miR-208a, miR-505, miR-144, miR-451, miR-125 
 
Target Gene 
Sample 208 * 505 144 451 125 
29   0.188824 2.396809 700.9776 11.65514 
30   1.389741 0.214802 362.4287 32.53896 
31   0.336543 0.035928 158.1674 1.087789 
32   0.293716   35.58316 11.45912 
Mean  0.552206 0.882513 314.2892 14.18525 
S.D  0.561794 1.314465 290.916 13.19388 
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S.E.M  0.280897 0.758907 145.458 6.59694 
N 0 4 3 4 4 
 
* miRNA 208 failed to be detected in any sample 
Ratio values from Real Time PCR for Time Point against each miRNA for Time Point B are 
shown in Table 9a-d below.  
 
Table 9a: Time point B. Calculated ratio values via excel per sample 2-26 with respect to 




















































































































































N 10 10 10 7 10 10 
 
Table 9b: Time point B. Calculated ratio values via excel per sample 2-26, with respect to 
their corresponding miR-208a, miR-505, miR-144, miR-451, miR-125 
 
Target Gene 
Sample  208 * 505 144 451 125 
2   0.247158983 0.365296475 622.7708824 46.92848177 
7   168.4634485 2.423479461 22596.90887 3900.550034 
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11           
12   0.889351362 0.611468736 1258.020085 134.5440273 
13   0.048866847 1.086808921 552.2280269 6.696803065 
14   5.884835511 2.481032343 3930.649048 21.67438332 
16   0.005987277 0.001306374 5.392007728 0.399839221 
20   0.273544017 1.17410892 389.2630335 35.09670964 
22   0.096962588 0.903395449 1318.068785 2.143227122 
23   3.113991608 3.637722529 2710.586184 125.1043675 
26 0.002476964 0.180734432 1.390399974 451.9846673 5.586211345 
Mean 0.002476964 17.92048811 1.407501918 3383.587159 427.8724084 
S.D #DIV/0! 52.92950671 1.118905265 6858.08131 1221.168859 
S.E.M #DIV/0! 16.73777966 0.353828912 2168.715732 386.1675001 
N 1 10 10 10 10 
 
 
Table 9c: Time point B. Calculated ratio values via excel per sample 29-32, with respect to 
their corresponding miR-1, miR-27, miR-133a, miR-133b, miR-29b, miR- 30a 
Sample 1 27 133a 133b 29b 30a 
29 502.4242 5466.888 169.1671 0.682188 11.40595 7190.75 
30             
31 0.061393 8.21405 0.75832 0.167859 0.017259 24.3367 
Mean 167.5152 1825.584 56.66204 0.284674 3.809243 2407.994 
S.D 290.0397 3153.463 97.43282 0.353876 6.578945 4141.995 
S.E.M 167.4545 1820.653 56.25287 0.20431 3.798356 2391.382 
N 3 3 3 3 3 3 
 
 
Table 9d: Time point B. Calculated ratio values via excel per sample 29-32, with respect to 




Sample 208 * 505 144 451 125 
29   84.1857316 38.42094312 27660.56527 2577.729085 
30           
31   0.779775886 0.020699954 223.9500939 50.36577773 
32   0.120893123 0.005143767 26.01924536 8.515618108 
 




Ratio values from Real Time PCR for Time Point against each miRNA for Time Point C are 
shown in Table 10a-dbelow.  
 
Table 10a: Time point C. Calculated ratio values via excel per sample 2-26, with respect to 
















































































































































































Table 10b: Time point C. Calculated ratio values via excel per sample 2-26, with respect to 
their corresponding miR-208a, miR-505, miR-144, miR-451, miR-125 
 
Target Gene 
Sample  208 * 505 144 451 125 
2   1.624889933 0.075816444 882.9068273 183.39882 
7   5.348897907 0.121446153 1141.638427 84.78699104 
11   0.302018899 0.222643151 178.7219748 44.23051519 
12   24.44782941 32.95619001 39534.90089 1845.379022 
13   0.29076426 0.334853558 4173.858383 65.10356731 
14   1.684781283 0.075910943 655.9276063 26.69445474 
16   0.080491909 0.097967349 3621.509551 73.31554471 
20   0.001532339 0.047220485 27.92680614 0.219050783 
22   0.279795308 0.021106798 108.4756777 20.53280594 
23   0.957278439 0.531064512 239.0926437 55.5910525 
26   2.585955054 1.540160931 1389.904216 91.29330181 
Mean #DIV/0! 3.418566795 3.274943666 4723.169364 226.4131933 
S.D #DIV/0! 7.14910701 9.853867252 11630.56227 539.1182128 
S.E.M #DIV/0! 2.155536867 2.971052765 3506.746469 162.5502572 
N 0 11 11 11 11 
 
Table 10c: Time point C. Calculated ratio values via excel per sample 29-32. with respect 
to their corresponding miR-1, miR-27, miR-133a, miR-133b, miR-29b, miR- 30a 
 
Target Gene 
Sample 1 27 133a 133b 29b 30a 
29 2.44286 2.883754 5.71241 0.006502 0.0155 4.492226 
30 1.088788 237.8754 24.50594 0.680998 0.045422 566.4767 
31 14.10424 29.4537 16.8276 0.112089 0.318979 213.9994 
32 5.891399 44.05437 12.02105 1.71907 0.041909 311.4601 
Mean 5.881821 78.56681 14.76675 0.629665 0.105452 274.1071 
S.D 5.842597 107.5645 7.929247 0.784358 0.142976 233.224 
S.E.M 2.921299 53.78225 3.964623 0.392179 0.071488 116.612 









Table 10d: Time point C. Calculated ratio values via excel per sample 29-32, with respect 
to their corresponding miR-208a, miR-505, miR-144, miR-451, miR-125 
 
Target Gene 
Sample 208 * 505 144 451 125 
29   0.398148 0.132557 57.88371 15.49169 
30   10.8479 3.512112 16620.88 186.6577 
31 0.175669 27.53595 0.976445 1226.82 108.55 
32 0.005035 0.940021 0.359806 1320.516 71.85636 
Mean 0.090352 9.930505 1.24523 4806.524 95.63894 
S.D 0.120657 12.68185 1.552742 7897.153 71.74099 
S.E.M 0.085317 6.340926 0.776371 3948.577 35.8705 
N 2 4 4 4 4 
 
 
* miRNA 208 failed to be detected in any sample. 
 
Ratio values from Real Time PCR for Time Point against each miRNA for Time Point D are 
shown in Table 11a-dbelow.  
 
Table 11a: Time point D. Calculated ratio values via excel per sample 2-26, with respect to 



































































































































































N 11 11 11 9 11 11 
 
 
Table 11b: Time point D. Calculated ratio values via excel per sample 2-26, with respect to 
their corresponding miR-208a, miR-505, miR-144, miR-451, miR-125 
 
Target Gene 
Sample  208 * 505 144 451 125 
2   0.64010569 0.166080894 955.847371 409.9064231 
7   27.00362044 1.56391954 6832.600541 394.403677 
11   0.71035356 0.2179977 239.0589407 158.3185599 
12   0.321438605 0.715334517 732.6311171 11.3450997 
13   0.03084167 0.105462157 157.3380331 0.177643344 
14   0.009297763 7.944141785 2996.393136 195.3970251 
16   0.183610902 0.03421399 172.8265059 103.8482879 
20   0.022549474 0.015155928 83.59193243 0.812921038 
22   0.98342984 0.022879977 124.1782277 16.12024637 
23   1.309119323 0.506412051 133.7741503 54.86524506 
26   0.2471984 9.183974311 2160.331742 4.263605236 
Mean  2.860142333 1.861415714 1326.233791 122.6780667 
S.D  8.01876496 3.356238559 2063.599957 153.452083 
S.E.M  2.417748605 1.011944001 622.1987977 46.26754387 
N 0 11 11 11 11 
 
 
Table 11c: Time point D.Calculated ratio values via excel per sample 29-32, with respect to 


















































Table 11d: Time point D. Calculated ratio values via excel per sample 29-32 with respect to 
their corresponding miR-1, miR-27, miR-133a, miR-133b, miR-29b, miR- 30a 
 
Target Gene 
Sample 208 * 505 144 451 125 
29   0.398148256 0.132556936 57.88371447 15.49168824 
30   10.84789901 3.512112499 16620.87837 186.6577379 
31 0.175669453 27.53595379 0.976445007 1226.819565 108.5499721 
32 0.005034742 0.940020922 0.359805956 1320.515636 71.85635703 
 
* miRNA 208 failed to be detected in any sample 
Further analysis of the calculated sample ratio values by means of GraphPad PRISM 
produced graphs for each time miRNA against each time point. 
3.10 Exclusion Criteria 
Once the miRNA sample values were calculated in Excel using the comparative ΔΔCT 
method and average was calculated for each miRNA for each of the time points. Any 
samples which were 5-fold above or below the mean were discarded.  
Ratio data that was included in the study post-outlier processing by miRNA is shown below 
in table 12-21.  
 
Table 12:  Included ratio data for miR-1 by Time point 
A B C D 
0.495879 0.090368 0.648573 2.142844 
2.280973 3.583213 3.093693 9.220367 
5.740927 0.883507 1.852167 7.448355 
3.461809 1.140407 0.223471 9.647018 
0.498143 0.054014 3.310611 0.846101 
2.607942 1.598431 0.313454 1.814233 
2.336094 0.090035 0.987276 2.44286 
2.994865 3.271854 1.273776 1.088788 
0.522808 0.111117 0.755377 14.10424 
0.399585 0.061393 0.390805 5.891399 
0.443932 0.059987     






Table 13: Included Ratio data for miR-27a by time point. 
A B C D 
  14.71081 15.53057 54.50568 
    84.29208   
    19.82366 41.6483 
99.63212 107.6757   6.372927 
29.81393   66.15322   
35.84429 23.23739 39.5486   
391.1921   19.69099 53.79039 
77.4656 129.4416     
338.5801 16.61412 50.46636 39.21465 
326.1033 188.3428 104.8192 59.48223 
47.80185 13.36692 51.21211 7.57153 
        
    66.94536   
  8.21405   29.4537 
    15.03932 44.05437 
 
Table 14: Included Ratio data for miR-133a by time point. 
A B C D 
2.005959 0.91578 0.67496 5.779825 
    5.910532   
10.73614   6.725743 15.09007 
7.550233 13.0695   0.215735 
6.946969   2.869579   
0.670672 1.458022 4.409779 71.25742 
38.9361   2.896319 12.73023 
4.387073 3.547855     
11.13983   0.838336 2.378358 
10.46042 5.383051 3.795416 0.754994 
2.212046 1.243214 8.200371 0.765269 
0.769272     5.71241 
0.77753   1.459717 24.50594 
  0.75832   16.8276 












Table 15: Included Ratio data for miR-133b by time point 
A B C D 
10.73614   6.725743 15.09007 
        
6.946969   2.869579   
0.670672 0.145709 4.409779   
38.9361 0.035719 2.896319 12.73023 
4.387073 0.263335     
11.13983   0.838336 2.378358 
10.46042 0.036589 3.795416 0.754994 
2.212046   8.200371   
0.769272 0.432195   5.71241 
0.77753 0.155288 1.459717   
  0.682188 0.567462   
      0.680998 
  0.167859     
      1.71907 
 
Table 16:  Included Ratio data for miR-29b by time point 
A B C D 
0.033947 0.043327 0.065038 0.393151 
    0.093193 1.435587 
0.029174   0.050087 0.129011 
0.126427 0.297997   0.039233 
0.078057   0.375001   
0.071039 0.04848 0.200747 1.48114 
      0.04512 
0.163759 0.524531   0.010852 
0.628408   0.148627 0.056316 
0.673204 1.449876 0.162708 0.668087 
0.328828 0.212679 0.307168 0.094129 
0.028512   0.946195 0.0155 
0.013325   0.147442 0.045422 
      0.318979 













Table 17: Included Ratio Data for miR-30a by time point 
A B C D 
309.7006 81.0632 153.7332 87.20622 
    447.435   
88.27827     45.13578 
104.0022 353.2198   48.88723 
53.97989 20.45525 389.9639   
31.68108 303.7682 58.4388 437.9649 
102.5972       
284.8018 93.27156     
216.9115 81.48007 57.12153 136.5405 
  22.47495   93.36015 
164.3125 41.73838 246.0801 81.01508 
    221.7049   
146.2681   589.022   
  24.3367   213.9994 
    197.7687 311.4601 
 
Table 18: Included Ratio Data for miR-505 by time point 
A B C D 
1.76517 0.247159 1.62489 0.640106 
    5.348898   
1.088062   0.302019 0.710354 
0.942073 0.889351   0.321439 
0.39907   0.290764   
0.437063   1.684781   
0.609239     0.183611 
1.709945 0.273544     
1.719329   0.279795 0.98343 
3.478435 3.113992 0.957278 1.309119 
0.385332   2.585955 0.247198 
0.188824     0.398148 
1.389741       
0.336543 0.779776     
0.293716   0.467121 0.940021 
 
Table 19: Included ratio data for miR-144 by time point 
 
A B C D 
  0.365296 882.9068 0.166081 
  2.423479 1141.638 1.56392 
0.309216   178.722 0.217998 
0.278699 0.611469   0.715335 
0.113794 1.086809   0.105462 
64 
 
  2.481032 655.9276   
0.342924     0.034214 
0.44459 1.174109   0.015156 
0.365703 0.903395 108.4757 0.02288 
1.437009 3.637723 239.0926 0.506412 
1.243971 1.3904 1389.904   
2.396809     0.132557 
0.214802       
  0.0207   0.976445 
      0.359806 
 
Table 20: Included Ratio data for miR-451 by time point 
 
A B C D 
745 622.7709 882.9068 955.8474 
    1141.638   
692.1017     239.0589 
1403.823 1258.02   732.6311 
892.5995 552.228 4173.858 157.338 
294.2082 3930.649 655.9276   
    3621.51 172.8265 
555.5239 389.263   83.59193 
1338.02 1318.069 108.4757 124.1782 
1346.122 2710.586 239.0926 133.7742 
310.1309 451.9847 1389.904   
700.9776   5686.541 57.88371 
362.4287   8243.706   
158.1674 223.9501   1226.82 
    676.7125 125 
Table 21: Included Ratio data for miR-125 by time point 
 
A B C D 
21.63356 46.92848 183.3988 409.9064 
    84.78699 394.4037 
84.89814   44.23052 158.3186 
89.38541 134.544     
21.42685 6.696803 65.10357   
  21.67438 26.69445 195.397 
189.9097   73.31554 103.8483 
51.25614 35.09671     
68.693   20.53281   
108.8587 125.1044 55.59105 54.86525 
10.44321   91.2933   
11.65514   682.1806   
32.53896   224.1777 186.6577 
  50.36578   108.55 




3.11 miRNA expression change graphs from GraphPad Prism 
 
The miRNA ratio values were used to construct the below graphs on GraphPad Prism to 
demonstrate the changes in miRNA expression levels across the 4 time points.  The anova 
test was performed on the data to test for a relationship between each of the time points: A= 
pre-RT, B=24-72h post-RT, C=3 months post-RT and D= 6 months post-RT. The student’s 

















































Figure 6A: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-1 at 
different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of RT, 
D=6 months post first dose of RT. Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: 
n=12, B: n=11, C: n=10, D: n=10), (p=0.0084). 
As can be seen from Figure 6a, levels decrease from time points A to B, and then rise from 
C through to time point D.  The Anova test revealed a significant difference in the expression 
of miR-1 between the different groups (p=0.0084). As the graph reveals the expression of 
miR-1 from time point B to D increases by more than three-fold and C to D by more than 3 









































































reveals the change from A to D (p=0.009), B to D (p=0.002) and C to D (p=0.003) and as 
tcarrying three star significance as illustrated in the graph above. 





























Figure 6b: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-1 
between time point A (baseline pre-RT reading) (n=12) and D (n=10) (6 months post RT reading) 
only. Expression was determined by quantitative real-time PCR and the data were normalized to U6 
as an internal control. Each data point is presented as mean± SEM (A: n=12; D: n=10), (p=0.0378). 
 
As seen in Figure 6b above there was a significant increase in the levels from time point A to 
D.  A students t-test in Fig 6b revealed a significant increase in miR-1 expression from time 









































































Figure 7a: Effects of left-sided radiotherapy on breast cancer patients on the expression of 
miR-451 at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months 
post-first dose of RT, D=6 months post first dose of RT. Expression was determined by 
quantitative real-time PCR and the data were normalized to U6 as an internal control. Each 
data point is presented as mean± SEM (A: n=12, B: n=9, C: n=11, D: n=11), (p=0.0120). 
As can be seen from Figure 7A, levels from A-C rose by more than 3-fold and then 
decreased from C-D by more than 5-fold. A one way ANOVA test revealed there to be a 
significant relationship between the groups p=0.0120. The Tukey test revealed the increase 













































































































Figure 7b: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-451 
between time point A (baseline pre-RT reading) (n=12) and D (n=11) (6 months post RT reading) 
only. Expression was determined by quantitative real-time PCR and the data were normalized to U6 
as an internal control. Each data point is presented as mean± SEM (A: n=12; D: n=11), (p=0.0321). 
 
As seen in Figure 7b there was a significant decrease in the levels from time point A to D.  A 
students t-test in Fig 7B revealed a significant decrease in miR-451 expression from time 
























































































































Figure 8a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-27a 
at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of RT, 
D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: 
n=8, B: n=8, C: n=11, D: n=9), (p=0.1387). 
As can be seen from Figure 8A, levels of miR-27a decreased by more than 3-fold by A t B, 
by more 4-fold from A to C and more than 5-fold A to D.  However the ANOVA test revealed 
no significant difference between these time points (A-B, A-C, B-C, B-D, C-D (p=0.1387). A 
71 
 
T-test was conducted to explore the difference between groups to A to D where there was 




































Figure 8b: Effects of left-sided radiotherapy on breast cancer patients on the expression of  miR-27a 
between time point A (baseline pre-RT reading) (n=8) and D (n=9) (6 months post RT reading) only. . 
Expression was determined by quantitative real-time PCR and the data were normalized to U6 as an 
internal control. Each data point is presented as mean± SEM (A: n=8 D: n=9), (p=0.0464). 
 
 
As seen in Figure 8b there was a significant decrease in the levels from time point A to D.  A 
students t-test in Fig 8B revealed a significant decrease in miR-27a expression from time 






































































Figure 9a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-125a 
at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of RT, 
D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: 
n=11, B: n=8, C: n=12, D: n=9), (p=0.0146). 
 
As can be seen in Figure 9A, levels of miR-125a increased by 3-fold between time points B-
D and A to D.  A one way ANOVA found the relationship between the groups to be 
statistically significant (p=0.0146). A Tukey HSD test did not reveal which groups were 
statistically significant. A LSD Test went onto reveal that the increase from B- D was 












































































































Figure 9b: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-125a 
between time point A (baseline pre-RT reading) (n=11) and D (n=9) (6 months post RT reading) only.  
Expression was determined by quantitative real-time PCR and the data were normalized to U6 as an 
internal control. Each data point is presented as mean± SEM (A: n=11 D: n=9) (p=0.0098)  
As seen in Figure 9b there was a significant increase in the levels from time point A to D.  A 
students t-test in Fig 9B revealed a significant decrease in miR-125a expression from time 

























































Considering significant relationships from time points A to D as shown in Figure 6b to 9b it 
can be seen that,  miR-1 expression increased significantly (p=0.0378)  from a mean miRNA 
ratio value of 1.9 at time point A (baseline pre-RT) to 5.5 at time point D (6 months post RT) 
which is nearly a 3 fold increase.miR-125a expression increased significantly (p= 0.0098)  
from a mean miRNA ratio value of 62.7 at time point A (baseline pre-RT) to 187 at time point 
D (6 months post-RT) which is more than a 3 fold increase. 
miR-451 expression decreased significantly (p=0.0321) from a mean miRNA ratio value of 
733 at time point A (baseline pre-RT) to 388 at time point D (6 months post-RT) which is 
more than a 2 fold decrease in level. 
miR-27a expression also decreased significantly (p=0.0464)  from a mean miRNA ratio 
value of 167 at time point A (baseline pre-RT) to 37  at time point D (6 months post RT) 



























































Figure 10a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-29b 
at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of RT, 
D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: 
n=12, B: n=6, C: n=9, D: n=14), (p=0.4050). 
 
As can be seen in Figure 10a there was minimal variation in the levels of miR-29b between 
time points A, B, C and D.  The ANOVA test revealed no significant difference between the 
time points (A-B, A-C, B-C, B-D, and C-D). There was no significant change in miR-29b 







































































































Figure 10b:Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-29b 
between time point A (baseline pre-RT reading) (n=12) and D (n=14) (6 months post RT reading) 
only.  Expression was determined by quantitative real-time PCR and the data were normalized to U6 
as an internal control. Each data point is presented as mean± SEM (A: n=12 D: n=14) (p=0.5892).  

























































































Figure 11a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-30a 
at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of RT, 
D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: 
n=10, B: n=9, C: n=9, D: n=9), (p=0.1128). 
 
As can be seen in Figure 11a there is not much variation in the levels of miR-30a between 
time points A, B, C and D. The ANOVA test revealed no significant difference between the 
time points (A-B, A-C, B-C, B-D, and C-D). There was no significant change in miR-30a 






































































































Figure 11b:  Effects of left-sided radiotherapy on breast cancer patients on the expression of 
miR-30a between time point A (baseline pre-RT reading) (n=10) and D (n=9) (6 months post 
RT reading) only.  Expression was determined by quantitative real-time PCR and the data 
were normalized to U6 as an internal control. Each data point is presented as mean± SEM 
(A: n=10 D: n=9) (p=0.7802)  
 



















































































Figure 12a: Effects of left-sided radiotherapy on breast cancer patients on the expression of 
miR-133a at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months 
post-first dose of RT, D=6 months post-first dose of RT. Expression was determined by 
quantitative real-time PCR and the data were normalized to U6 as an internal control. Each 
data point is presented as mean± SEM (A: n=12, B: n=7, C: n=11, D: n=12) (p=0.3443). 
 
 
As can be seen in Figure 12a there is no significant variation in the levels of miR-133a 
between time points A, B, C and D. The ANOVA test revealed no significant difference 
between the time points (A-B, A-C, B-C, B-D, and C-D). There was no significant change in 

































































































Figure 12b: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-
133a between time point A (baseline pre-RT reading) (n=12) and D (n=12) (6 months post RT 
reading) only.  Expression was determined by quantitative real-time PCR and the data were 
normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: n=12, D: 
n=12) (p=0.4357). 


























































































Figure 13a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-
505a at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of 
RT, D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and 
the data were normalized to U6 as an internal control. Each data point is presented as mean± SEM 
(A: n=14, B: n=5, C: n=9, D: n=9), (p=0.2703). 
 
 
As can be seen in Figure 13a there is no significant variation in the levels of miR-505 
between time points A, B, C and D. The ANOVA test revealed no significant difference 
between the time points (A-B, A-C, B-C, B-D, and C-D). There was no significant change in 










































































































Figure 13b Effects of left-sided radiotherapy on breast cancer patients on the expression of 
miR-505 between time point A (baseline pre-RT reading) (n=14) and D (n=9) (6 months post 
RT reading) only.  Expression was determined by quantitative real-time PCR and the data 
were normalized to U6 as an internal control. Each data point is presented as mean± SEM 
(A: n=14, D: n=9) (p=0.2703)  
 
 





























































































Figure 14a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-144 
at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of RT. 
D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± SEM (A: 
n=10, B: n=10, C: n=7, D: n=12), (p=<0.0001) 
As can be seen in Figure 14a, there is more than 900 fold increase from A (0.7) to B (656), 
more than a 465 fold increase from A (0.7)  to C (656) accompanied by more than 1600 fold 
decrease from C (656) to D (0.40). Using the Anova test, the increase from A (n=10) to C 
(n=7) was found to be statistically significant (p=<0.01) as well as the decrease from C (n=7) 







































































































Figure 14b: Effects of left-sided radiotherapy on breast cancer patients on the expression of 
miR-144 between time point A (baseline pre-RT reading) (n=10) and D (n=12) (6 months 
post RT reading) only.  Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± 
SEM (A: n=10, D: n=12) (p=0.1765)  
 






































































Figure 15a: Effects of left-sided radiotherapy on breast cancer patients on the expression of miR-
133b  at different time point A =pre-RT, B =24-72h post first dose of RT, C=3 months post-first dose of 
RT, D=6 months post-first dose of RT. Expression was determined by quantitative real-time PCR and 
the data were normalized to U6 as an internal control. Each data point is presented as mean± SEM 
(A: n=10, B: n=8, C: n=9D: n=7), (p=0.0006).  
miR-133b levels decreased significantly (p=<0.001) from a mean miRNA ratio at  time point 
A (baseline pre-RT) of 8 to 0.2 at time point B (24-72h post RT), which is more than a 40 fold 
decrease. miRNA levels continued from then on to rise significantly (p=<0.01)  as the mean 
miRNA ratio increased at time point B (0.2) to 3.5 at time point C (3 months post RT) which 
is an 18 fold increase. From time point B, the mean ratio value of 0.2 was seen to rise 
significantly (p=<0.01) compared to 5.5 at time point D (6 months post RT) which is a 24 fold 
increase. A one way ANOVA test revealed the changes between the groups to be significant  
(P=0.0006). The Tukey test did not reveal the group in which the significant change relied 

































































































Figure 15b: Effects of left-sided radiotherapy on breast cancer patients on the expression of 
miR-133b between time point A (baseline pre-RT reading) (n=10) and D (n=7) (6 months 
post RT reading) only.  Expression was determined by quantitative real-time PCR and the 
data were normalized to U6 as an internal control. Each data point is presented as mean± 
SEM (A: n=10, D: n=7) (p=0.8125).  
 
A student’s t-test in Fig 15b revealed no significant change from A to D in miR-133b 
(P=0.8125). 
As can be seen from Figures 10a to 13b the levels of miR-29b, miR-30a, miR-133a, miR-505 
did not change significantly from time point A to D neither were they noted to have any 













































Section 4. Discussion 
 
4.1 Background, Purpose and Results 
 
Though survival rates following BC have improved a great deal over the past few decades, 
there is a greater long term concern over the adverse effects of treatment, especially as 
patients live for longer (Chapman et al 2008).  
 
Unfortunately one major risk of radiation is the damaging effect this has on the heart, in 
particular where cancer patients receive left-sided RT (Darby et al 2013). Cardiac 
dysfunction due to radiation involves a spectrum of disease processes in patients who have 
undergone mediastinal, thoracic, or breast RT, and may involve any cardiac structure, 
including the pericardium, myocardium, valves, conduction system, and coronary arteries 
(Darby et al 2013). RIHD encompasses a broad spectrum of acute and coronary conditions 
including perfusion abnormalities, myocardial oedema, scarring and fibrosis, valvular 
disease, CAD and acute MI (Vasu et al 2013). 
 
There is currently an urgent need to find a more specific, sensitive and clinically valid 
biomarker which can be used for the earlier detection of RIHD. miRNAs have appeared as 
ideal candidate biomarkers for early stage RIHD diagnosis due to their non-invasive, fluid-, 
tissue-, organ- and disease specific nature. To date there is no study which focuses upon 
the utility of previously recognised cardiovascular disease miRNAs as a marker for RIHD 
and specifically in the context of left-sided breast irradiation.  The aim of this novel work was 
to thus to evaluate whether miRNAs which have been previously linked to cardiac damage 
are differentially expressed in BC patients treated for left sided RT and thus could potentially 





It is important to note that of the 15 BC patient in this study, none to date have developed 
clinical signs of cardiotoxicity at their most recent 6 month-review post RT and these patients 
would not have been reviewed since then unless they became symptomatic for myocardial 
injury. These patients are however due for their 5 year-review this year where they will be 
assessed for their cardiac function through clinical history taking, miRNA, CMR imaging, 
Troponin and BNP analysis once again where their clinical presentation and complaints may 
be very different.  It is important to note that these patients were treated with low doses of 
RT in a hypofractionated therapy regime which is known to minimise risk of adverse effects 
of RT (Kim et al 2016). At doses above 30 Gy, radiation related heart disease may occur 
within a year or two of exposure and risk increases with higher radiotherapy dose, therefore 
it could be that these patients have undetected signs of myocardial change (Beikei et al 
2012 ).  Though these patients received 40 Gy in 15 fractions over 5 weeks, the mean dose 
to the whole heart, left ventricle, and left coronary artery was 1.4 Gy, 2.0 Gy, and 6.6 Gy, 
respectively and they were deemed as receiving low-dose radiation where the latent period 
can be much longer and often be more than a decade (Darby et al 2013).  
 
All patients included in this study had normal levels of Troponin I, below the limit of detection 
for the assay (<0.04 µg/L). All measures of BNP were also normal (0.6-28.9 pmol/L). CMR 
imaging results which are a more specific and sensitive measure of stroke volume and 
ejection fraction compared to echocardiography (Lancelloti et al 2013) showed that patients 
had no significant changes in stroke volume or EF.  
 
Significant miRNA expression changes were observed when utilising students t-test 
comparing time point A and D (n=8-15) for: miR-1 (increased nearly 3-fold,  p=0.0378), miR-
27a (decreased nearly 4-fold, P=0.0464), miR-451 (decreased more than 2-fold, P= 0.0321), 
and miR-125a (increased more than 3-fold, P=0.0098).miR-144 was also found to be 
upregulated from A (n=10) to C (n=7) (P≤0.01) and decreased back to baseline levels from 
C (n=7) to D (n=12) (P≤0.0001). Other statistically significant relationships include a more 
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than 3-fold increase in the levels of miR-1 from time point B  to D (p=0.002) and C to D 
(p=0.003).  miR-125 levels also increased by more than 2-fold between time points B to D 
(p=0.031). miR-144a levels increased by more than 465-fold from time point A to C (p<0.01) 
and then decreased by more than 1600 fold from time point C to D (p<0.0001). miR-133b 
levels  were found to significantly decrease by more than 40-fold between A (n=10) to B 
(n=8) (p=0.015). The expression levels of miR-133a, miR-29b, miR-30a and miR-505 were 
not altered 6 months post-radiotherapy. The expression of miR-208a was undetectable at all 
time points in this study (n=7-13). 
 
These 6 candidate markers of cardiovascular disease are all dysregulated in the acute 
stages of myocardial injury (Darby et al 2013).Our findings might suggest of acute injury 
incidence detectable by miRNA profiling, which was not picked up by troponin, BNP or 
imaging, suggesting a more sensitive and specific role of miRNA biomarker detecting RIHD 
at an early stage. This would allow adjuvant therapy to be administered to aptinets to 
minimise the risk of cardiac damage and allow for RT regimes to be planned more effectively 
as treatment progresses to once again minimise the risk of cardiac damage.  
 
Cardiac specific miRNA miR-1is suggested to plan essential role in endothelial function and 
angiogenesis and cardiac myocyte differentiation. It has previously been reported that miR-1 
is a more sensitive biomarker that the gold standard biomarker Troponin in the diagnosis of 
acute coronary syndrome and is significantly increased in these cases (Ghao et al 2015).  In 
our study miR-1 was also increased which suggests the existence of acute myocardial 
change in these patients. Depletion of miR-1 levels have also been show to cause a loss of 
conductivity through potassium channels resulting in cardiac arrhythmias thus an increase in 
expression levels may be a response to conduction abnormalities a a result of RIHD (Yang 
et al 2008).  Acute coronary syndromes refer to a spectrum of clinical presentations ranging 
from arrhythmia, MI, and even unstable angina. However the diagnostic value of miR-1 in 
CAD which is also an important manifestation of RIHD may of limited value. Studies have 
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found no differential regulation of CAD patients compared to control group patients (Gacori 
et al 2016).  
 
miR-125a has previously been reported as increased in patients with HF in patients with 
reduced ejection fraction (Vegter et al 2015).  Our study also found levels of miR-125a to 
rise significantly from the start to the end of RT. Though it is unlikely that patients would 
have developed HF so promptly, the rise could be suggestive of damage to the myocardium. 
Interestingly, it has been reported that miR-125a partly regulates the inflammatory response 
in heart muscle cells and an increase is suggestive of an inflammatory response. It is known 
that one of the causes of RIHD is the host immune response to radiation which makes miR-
125a a particularly valid marker in the contact of RIHD. It is likely therefore that the 
significant increase in miR-125a was related to the immune response to the radiation hosted 
by the heart muscle cells in response to the radiation.  
 
A decrease in miR-27a has been shown to increase the production of cardioprotective 
genes. miR-27a is specifically noted to be an inhibitor of angiotensin converting enzymes 
(He  et al 2011).  In fact, it has even been suggested that modulation of mIR-27a could serve 
as a useful tool in preventing or reducing incidence of cardiovascular disease (Consistent up 
regulation of miR-27a was found during ischaemic stroke (Sepramaniam et al 2014). Our 
study agreed with these findings in that levels of miR-27a decreased from the start to the 
end of radiotherapy. A decrease in miR-27a could be suggestive of damage to the myocytes 
and therefore a reduction in the proportion of cardioprotective genes. It would be interesting 
to note whether levels of miR-27a would now be restored to normal levels thus promoting 
the increase in cardioprotective genes now that much time has elapsed since their last dose 
of RT. miR-27a as has also been noted to be decreased in cases of acute HF and correlates 




It has been reported that miR-451 is significantly decreased in cardiovascular disease 
(Zheng et al 2016). It has also been shown that miR-451 protects against atherosclerotic 
plaque formation and therefore can protect against CAD. In our study levels of miR-451 were 
found to significantly decrease, which would be suggestive cardiomyocyte damage, an 
increase in miR-451 and thus a decrease in the production of cardioprotective genes. 
 
It has been shown that increased levels of miR-144 confer protection against stimulated 
ischaemia/reperfusion injury induced cardiomyocyte cell death (Zhang et al 2010) . In our 
study we found that miR-144 levels peaked at 3 months post=RT and then decreased again 
at 6 months post-RT. Upregulation at time point C would suggest occurrence of 
cardiomyocyte cell damage which induced miR-144 upregulation after which at time point D, 
another 3 months post RT, levels again subsided with improving cardiomyocyte cell function 
(Zhang et al 2010). 
 
We also noted that miR-133b levels were seen to significantly drop at baseline ART and 24-
72 hour post RT. Levels then continued to rise from time point B to time point C and D 
significantly. Upregulation of miR-133b is noted in cases of ischaemic reperfusion injury and 
an increase is noted to be associated with improved myocyte function and recovery from 
ischaemia. In our study levels dropped post administration of RT suggesting cardiomyocyte 
cell damage and the increase in levels between time point B-C and C-D are suggestive of 
upregulation of mIR-133b as a compensatory mechanism to improve cardiomyocyte 
function. 
 
We found that within our study miR-208a could not be detected in any time point in any of 
these samples (N=7-13). The study by Wang et al has shown that miR-208, miR-1 and miR-
133 could be detected at an early stage (within a few hours) of the onset of symptoms in the 
plasma of AMI patients when compared to a control group. However,the expression of miR-
208a was undetectable in the control subjects. Furthermore,miR-208a expression was 
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elevated at anearlier stage than cTnI. Interestingly miR-208a was found to be elevated in all 
patients whereas cTNI was only detected in 85% of patients.However, a study conducted 
byD’Alessandra et al showed that miRNA 208a was not detected in all AMI patients. 
However, this variation compared to the group of Wang et al may have been due to the fact 
that D’Alessandra et al collected the samples approximately 9 hours post the onset of 
myocardial injury whereas Wang et al collected them at 4 hours post injury. It is known in the 
literature that miRNA 208a peaks within the first2 hours of myocardial injury onset and 
therefore it is valid that no miRNA 208a would have been detected at the 9 hour stage. None 
of our samples were collected and processed within 1-2 hours post administration of RT and 
therefore we may have missed the cut off for the differential readings of miR-208a in our 
clinical samples. This perhaps also demonstrates a limitation with this miRNA, in that though 
sensitive and specific, only prompt readings would be of any clinical value. However as it is 
not usually detected this marker could also be useful in the diagnosis of AMI as suggested 
previously if timed correctly due to its highly specific nature (Wang et al 2010).  
 
The expression levels of miR-133a, miR-29b, miR-30a andmiR-505werenot altered 6 
months post-radiotherapy. The expression of miR-208a was undetectable in this study (n=7-
13). Though one may initially assume that this means there was no cardiotoxic change as 
these markers were not differentially regulated, it is more likely that mechanism of RIHD 
injury did not involve the dysregulation of these microRNAs (Darby et al 2006) 
 
4.2 Limitations of the study 
 
The largest limitation of this study currently is that these patients have not yet had their 5 
year review and it is not yet known whether following on from their last 6 month review 
whether any patients have developed cardiotoxicity. Therefore form our study it cannot be 





In this study, a single consultant cardiologist was responsible for reviewing the CMR images. 
The consultant cardiologist was not informed of the radiation dose and completely blinded to 
the study but was aware that these patients had been recruited for research purposes as 
well clinical diagnostic purposes. Although this may ensure a consistent approach to 
interpretation there are numerous limitations to this approach. 
It would also have been advisable to not inform the consultant cardiologist that these 
patients were recruited into the research study to ensure that the patients were detected for 
cardiac damage as would any other routine patient. This could cause positive bias in which 
findings may be overestimated in a bid to estimate findings that may not be objectively 
present. Secondly, this could lead to negative bias in which findings may be missed by 
adopting an over-cautious approach. Inter-assay variability may occur whereby simply 
reviewing images on different days may cause a difference in interpretation and errors. This 
inter-assay variability could also have occurred in the microRNA analysis phase of the 
experiments as the plates were run over different days which could have led to experimental 
errors due to inconsistent laboratory practice. Intra-assay variability in the interpretation of 
images could have also occurred whereby variation in interpretation occurred from reviewing 
one scan to another and a ‘normal’ scan  being specific and unique to each individual 
patient. Intra-assay variability could have also occurred in the microRNA analysis phase as 
replicates were loaded by hand on each plate and thus experimental errors could have 
arisen due to variation in pipetting and inaccuracies in the loading of samples.  
 
In an ideal experimental design to add more robustness to the experiment it would be 
beneficial to have a control group consisting of healthy patient volunteers who do not have 
cardiovascular disease as disease states such as hypercholesterolaemia are known to 
cause a differential expression of miRNAs (Chen et al 2015). Furthermore, miRNAs need to 
be profiled in patients known of suffering from RIHD or TIC in order to confidently ascertain 




This study undoubtedly would also need to be conducted in a larger number of patients in 
order to clinically validate these results. The N number for our study was 15 and these 
findings in order to be deemed as clinically applicable would have to be replicated in a much 
larger patient cohort. Our power calculation has also revealed at the beginning of the study 
that we required greater than 15 patients per group in order to ensure statistical power to our 
findings, unfortunately due to patient retention and the fact samples from a larger study were 
used we could not achieve this. Therefore to add more statistical power we would need more 
recruits per group.  
 
If more time was available then more time would have been spent on optimising the method. 
We used 1ml of plasma in our study as this seemed to give us acceptable quality and 
quantities of detectable miRNAs. However it has been suggested in the literature that 2-3ml 
of plasma/serum must be processed in order to obtain sufficient miRNA levels (Chen et al 
2008). 
 
As will be evident with the results in this study we adopted a stringent process for discarding 
outliers. There were outliers present within our study which may have been avoided if better 
experimental technique was used such as quicker processing of samples and reduction in 
the risk of contamination. Adequate spinning of the samples is key to reducing the proportion 
of contamination by cellular components (Zampetaki et al 2012).  
 
There are however also several challenges regarding the analysis of circulating miRNAs: 
short length, unequal melting temperatures, existence of miRNAs which have only single 
nucleotide differences, and their low abundance High throughput sequencing technologies 
offer a unique opportunity for detecting and profiling miRNA pools with unprecedented 
sensitivity. However the cost of these is incredibly high and thus only feasible for a limited 




For most laboratories however real time PCR as used in this study for the quantification of 
miRNA remains the gold standard for assessing circulating miRNAs in large clinical studies 
with its superior sensitivity compared to northern blotting, cloning, primer extension and 




Our study has shown that miR-1, miR-27a, miR-125 and miR-451 were altered from the pre-
radiation to the 6 month post-radiation stage in left sided RT BC patients, whereas imaging 
and circulation cardiac injury protein biomarkers did not change at all. We also showed that 
miR-144 and miR-133b shows a differential regulation pattern in response to RT. As none of 
the patients within this study developed clinically diagnosed cardiotoxicity as a result of 
radiation, the link between RIHD as a cause of these expressional  changes  cannot be 
established. However this study does highlight that miRNAs warrant further investigation in 
larger patient cohorts for potential as early stage biomarkers of RIHD as changes in 
expression patterns are seen.  
4.4 Future Perspectives 
 
In order to now move to clinically validating this technique and measurement of these 
miRNAs there are a number of steps that need to be taken. The results from these studies 
would need to be validated in a larger patient cohort. It would also be recommended that 
miRNA Array analysis be carried out within samples in order to start from the beginning in 
seeing which miRNA are differentially regulated in RIHD. We chose a panel of 11 
microRNAs we knew from the literature were previously associated with cardiovascular 
disease. However, the mechanism by which RIHD induces heart disease is not fully 
understood. A lack of understanding of the different pathways may mean that this study did 
not focus on other miRNAs which may be clinically significant in the context of RIHD and 
may have been missed, therefore utilising miRNA Array analysis would ensure that many 
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more miRNAs are checked and screened for an not just those which are linked to 
cardiovascular disease.  
 
For the use of any biomarker clinically valid cut offs or reference ranged need to be 
established. Therefore, by investigating values of the microRNAs of interest in healthy 
patients, patients with different co-morbidities, those with cardiovascular disease, those with 
cancer, those with RIHD, appropriate reference ranges could be established for each group. 
Importantly in the context of miRNAs as genomic biomarkers and represented in a huge 
range of organs and tissues, investigation needs to be carried out to the effect of age, sex 
and different co-morbidities which have all been noted to cause differential expression in 
their levels (Darby et al 2013). 
 
There has also been concern in the literature that miRNA signals from BC may interfere with 
signals from therapy induced cardiotoxicity. By adopting miRNA analysis and investigating 
the molecular mechanisms further by which microRNA can be dysregulated in BC, other 
cancers, and therapy induced cardiotoxicity will help broaden our understanding of which 
microRNAs serve as the best targets for RIHD. 
 
The hope therefore remains that if a panel of specific and sensitive microRNAs to RIHD can 
be defined with cut offs and reference ranges then microRNAs may indeed prove to become 
a valid diagnostic tool for early identification and assessment of RIHD instead of using 
imaging and Troponin and BNP analysis which, as discussed, have their limitations. 
Clinically this would allow adjuvant therapy to be administered to patients in order to 
minimise the risk of cardiac damage and allow for RT regimes to be planned more effectively 














Table A: Patient 2, 7 and 11 Cq Values obtained from RT-PCR 
 
Target Sample Ct Target Sample Ct Target Sample Ct 
U6 2A 34.19 U6 7A 38.56 U6 11A 33.45 
U6 2A 36.04 U6 7A 39.20 U6 11A 33.40 
1 2A   1 7A 32.90 1 11A 32.48 
1 2A 35.20 1 7A 32.96 1 11A 32.02 
27a 2A 31.13 27a 7A 27.20 27a 11A 31.10 
27a 2A 32.41 27a 7A 26.43 27a 11A 31.88 
133a 2A 33.54 133a 7A 29.86 133a 11A 30.73 
133a 2A 34.76 133a 7A 29.87 133a 11A 29.50 
133b 2A   133b 7A   133b 11A 37.02 
133b 2A   133b 7A 39.59 133b 11A 37.37 
29b 2A 39.07 29b 7A 36.43 29b 11A 38.48 
29b 2A   29b 7A 36.29 29b 11A 38.57 
30a 2A 26.48 30a 7A 27.49 30a 11A 27.01 
30a 2A 27.37 30a 7A 27.78 30a 11A 26.91 
208a 2A   208a 7A   208a 11A   
208a 2A   208a 7A 39.87 208a 11A   
505 2A 34.14 505 7A 32.58 505 11A 33.63 
505 2A 34.72 505 7A 33.67 505 11A 33.03 
144 2A   144 7A 34.35 144 11A 35.33 
144 2A   144 7A 34.89 144 11A 34.93 
451 2A 24.96 451 7A 24.81 451 11A 23.77 
451 2A 25.96 451 7A 23.37 451 11A 24.26 
125 2A 30.11 125 7A 27.91 125 11A 26.91 
125 2A 31.33 125 7A 27.39 125 11A 27.13 
U6 2B 33.17 U6 7B 38.03 U6 11B Ins 
U6 2B 34.11 U6 7B 39.66 U6 11B Ins 
1 2B 36.64 1 7B 33.85 1 11B Ins 
1 2B   1 7B 34.02 1 11B Ins 
27a 2B 29.86 27a 7B 27.84 27a 11B Ins 
27a 2B 29.83 27a 7B 27.33 27a 11B Ins 
133a 2B 32.99 133a 7B 33.12 133a 11B Ins 
133a 2B 34.64 133a 7B 31.51 133a 11B Ins 
133b 2B   133b 7B   133b 11B Ins 
133b 2B   133b 7B 36.44 133b 11B Ins 
29b 2B 38.78 29b 7B 38.39 29b 11B Ins 
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29b 2B 38.03 29b 7B 36.88 29b 11B Ins 
30a 2B 27.40 30a 7B 26.32 30a 11B Ins 
30a 2B 27.37 30a 7B 24.04 30a 11B Ins 
208a 2B   208a 7B   208a 11B Ins 
208a 2B   208a 7B   208a 11B Ins 
505 2B 37.12 505 7B 30.75 505 11B Ins 
505 2B 35.33 505 7B 32.16 505 11B Ins 
144 2B   144 7B 37.14 144 11B Ins 
144 2B 35.56 144 7B 38.08 144 11B Ins 
451 2B 24.71 451 7B 25.44 451 11B Ins 
451 2B 24.31 451 7B 24.41 451 11B Ins 
125 2B 29.98 125 7B 27.05 125 11B Ins 
125 2B 27.71 125 7B 27.17 125 11B Ins 
U6 2C 33.03 U6 7C 35.10 U6 11C 31.88 
U6 2C 33.22 U6 7C   U6 11C 31.60 
1 2C   1 7C 33.40 1 11C 30.35 
1 2C 33.84 1 7C 33.53 1 11C 31.91 
27a 2C 29.60 27a 7C 28.58 27a 11C 26.81 
27a 2C 28.88 27a 7C 28.83 27a 11C 29.02 
133a 2C 33.62 133a 7C 32.50 133a 11C 28.46 
133a 2C 33.77 133a 7C 32.56 133a 11C 30.13 
133b 2C   133b 7C 39.52 133b 11C 36.54 
133b 2C 39.01 133b 7C 38.28 133b 11C 38.62 
29b 2C 36.17 29b 7C 38.59 29b 11C 36.02 
29b 2C 39.16 29b 7C 38.45 29b 11C 36.12 
30a 2C 28.58 30a 7C 26.56 30a 11C 27.20 
30a 2C 25.06 30a 7C 26.07 30a 11C 26.66 
208a 2C   208a 7C   208a 11C   
208a 2C   208a 7C   208a 11C   
505 2C 32.85 505 7C 33.02 505 11C 33.75 
505 2C 32.14 505 7C 32.40 505 11C 33.19 
144 2C 37.47 144 7C 38.15 144 11C 33.70 
144 2C 36.47 144 7C 38.12 144 11C 34.22 
451 2C 23.58 451 7C 24.84 451 11C 24.28 
451 2C 23.16 451 7C 25.05 451 11C 24.24 
125 2C 25.69 125 7C 29.09 125 11C 26.24 
125 2C 25.54 125 7C 28.38 125 11C 26.33 
U6 2D 36.54 U6 7D 37.90 U6 11D 31.74 
U6 2D 35.30 U6 7D 35.00 U6 11D 30.89 
1 2D 35.25 1 7D 32.34 1 11D 29.08 
1 2D 34.42 1 7D 31.10 1 11D 27.30 
27a 2D 30.55 27a 7D 27.35 27a 11D 25.79 
27a 2D 29.79 27a 7D 27.19 27a 11D 26.47 
133a 2D 33.39 133a 7D 30.55 133a 11D 27.34 
133a 2D 33.89 133a 7D 30.75 133a 11D 27.70 
133b 2D   133b 7D 37.14 133b 11D 37.39 
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133b 2D   133b 7D 36.70 133b 11D 35.75 
29b 2D 37.89 29b 7D 36.78 29b 11D 34.05 
29b 2D   29b 7D 35.53 29b 11D 35.01 
30a 2D 30.65 30a 7D 25.46 30a 11D 26.03 
30a 2D 28.45 30a 7D 25.40 30a 11D 25.65 
208a 2D   208a 7D   208a 11D   
208a 2D   208a 7D   208a 11D   
505 2D 37.07 505 7D 32.33 505 11D 32.27 
505 2D 36.07 505 7D 32.30 505 11D 31.35 
144 2D 39.96 144 7D 36.70 144 11D 33.59 
144 2D 37.36 144 7D 35.28 144 11D 33.55 
451 2D 26.31 451 7D 24.35 451 11D 23.47 
451 2D 25.83 451 7D 24.32 451 11D 23.49 
125 2D 27.77 125 7D 28.48 125 11D 24.01 
125 2D 26.72 125 7D 28.34 125 11D 24.19 
 
As can be seen in table A for patient 2, 7 and 11 Cq Values obtained from RT-PCR, as can 
be seen from this table sample 11b was insufficient for analysis. Furthermore mIR-208a was 
not detected in these patients 
 
 
Table B: Patient 12, 13 and 14 Cqvalues as obtained from RT-PCR 
Target Sample Ct Target Sample Ct Target Sample Ct 
U6 12A 33.61 U6 13A 34.07 U6 14A 32.95 
U6 12A 32.33 U6 13A 34.27 U6 14A 33.10 
1 12A 30.53 1 13A 35.84 1 14A 35.06 
1 12A 30.73 1 13A 31.54 1 14A 33.49 
27a 12A 26.67 27a 13A 28.93 27a 14A 27.86 
27a 12A 26.07 27a 13A 29.67 27a 14A 27.87 
133a 12A 30.36 133a 13A 31.00 133a 14A 32.90 
133a 12A 29.84 133a 13A 31.81 133a 14A 34.82 
133b 12A   133b 13A 34.89 133b 14A 39.18 
133b 12A 39.80 133b 13A 38.64 133b 14A   
29b 12A 36.09 29b 13A 37.55 29b 14A 37.61 
29b 12A 36.09 29b 13A 38.18 29b 14A 36.38 
30a 12A 26.60 30a 13A 28.38 30a 14A 31.28 
30a 12A 26.02 30a 13A 28.46 30a 14A 27.19 
208a 12A   208a 13A   208a 14A   
208a 12A   208a 13A 39.59 208a 14A   
505 12A 33.80 505 13A 34.65 505 14A 34.36 
505 12A 32.31 505 13A 37.23 505 14A 34.10 
144 12A 34.82 144 13A 36.34 144 14A 35.75 
144 12A 35.33 144 13A 39.91 144 14A 38.17 
451 12A 22.89 451 13A 24.52 451 14A 24.50 
451 12A 22.20 451 13A 24.26 451 14A 25.21 
125 12A 26.68 125 13A 29.27 125 14A 30.88 
125 12A 26.50 125 13A 30.36 125 14A 30.21 
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U6 12B 31.37 U6 13B 32.11 U6 14B 34.25 
U6 12B 33.03 U6 13B 30.73 U6 14B 33.76 
1 12B 30.01 1 13B 31.75 1 14B 33.80 
1 12B 30.82 1 13B 31.79 1 14B 33.88 
27a 12B 24.82 27a 13B 29.84 27a 14B 28.73 
27a 12B 26.10 27a 13B 29.20 27a 14B 34.00 
133a 12B 29.51 133a 13B 33.08 133a 14B 34.13 
133a 12B 28.53 133a 13B 33.01 133a 14B 32.89 
133b 12B 34.19 133b 13B 37.08 133b 14B 35.61 
133b 12B 35.77 133b 13B 35.39 133b 14B 36.61 
29b 12B 33.43 29b 13B 37.40 29b 14B 38.68 
29b 12B 34.52 29b 13B 37.60 29b 14B 38.06 
30a 12B 23.66 30a 13B 27.08 30a 14B 25.54 
30a 12B 24.07 30a 13B 27.69 30a 14B 26.19 
208a 12B   208a 13B   208a 14B   
208a 12B   208a 13B   208a 14B   
505 12B 32.41 505 13B 39.82 505 14B 31.88 
505 12B 32.66 505 13B 34.15 505 14B 31.04 
144 12B 33.57 144 13B 31.02 144 14B 32.94 
144 12B 33.02 144 13B 35.38 144 14B   
451 12B 22.05 451 13B 22.26 451 14B 22.45 
451 12B 22.15 451 13B 23.23 451 14B 21.69 
125 12B 25.54 125 13B 28.72 125 14B 29.56 
125 12B 25.30 125 13B 29.17 125 14B 29.62 
U6 12C 39.57 U6 13C 34.73 U6 14C 33.27 
U6 12C 38.08 U6 13C 33.22 U6 14C 31.51 
1 12C 33.46 1 13C 29.28 1 14C 35.88 
1 12C 31.98 1 13C 30.80 1 14C 33.33 
27a 12C 28.22 27a 13C 28.02 27a 14C 27.25 
27a 12C 29.41 27a 13C 28.41 27a 14C 27.70 
133a 12C 32.85 133a 13C 36.00 133a 14C 30.21 
133a 12C 34.91 133a 13C 30.81 133a 14C 32.63 
133b 12C   133b 13C 32.55 133b 14C   
133b 12C 38.59 133b 13C 35.15 133b 14C 34.59 
29b 12C 36.79 29b 13C 35.38 29b 14C 34.81 
29b 12C 35.33 29b 13C 36.36 29b 14C 35.68 
30a 12C 28.00 30a 13C 25.58 30a 14C 27.32 
30a 12C 26.97 30a 13C 25.49 30a 14C 25.73 
208a 12C   208a 13C   208a 14C   
208a 12C   208a 13C   208a 14C   
505 12C 34.37 505 13C 35.88 505 14C 31.71 
505 12C 34.49 505 13C 36.15 505 14C 32.81 
144 12C 34.23 144 13C 38.00 144 14C   
144 12C 33.42 144 13C 34.04 144 14C 35.23 
451 12C 23.73 451 13C 22.43 451 14C 23.45 
451 12C 23.78 451 13C 21.53 451 14C 22.85 
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125 12C 28.14 125 13C 27.71 125 14C 28.20 
125 12C 28.21 125 13C 33.17 125 14C 27.22 
U6 12D 32.10 U6 13D 26.95 U6 14D 32.87 
U6 12D 31.53 U6 13D 26.16 U6 14D 35.12 
1 12D 33.04 1 13D 31.12 1 14D 33.64 
1 12D 33.06 1 13D 32.33 1 14D 31.28 
27a 12D 29.10 27a 13D 29.50 27a 14D 28.56 
27a 12D 29.28 27a 13D 27.68 27a 14D 27.35 
133a 12D 34.19 133a 13D 30.74 133a 14D 28.87 
133a 12D 33.87 133a 13D 30.41 133a 14D 28.13 
133b 12D 37.29 133b 13D 39.48 133b 14D 39.80 
133b 12D 38.12 133b 13D 39.24 133b 14D 36.82 
29b 12D 36.80 29b 13D 35.20 29b 14D 33.15 
29b 12D 36.17 29b 13D 35.16 29b 14D 34.02 
30a 12D 26.38 30a 13D 25.06 30a 14D 25.08 
30a 12D 26.03 30a 13D 23.07 30a 14D 25.76 
208a 12D   208a 13D   208a 14D   
208a 12D   208a 13D   208a 14D   
505 12D 33.32 505 13D 32.18 505 14D 39.61 
505 12D 33.74 505 13D 31.00 505 14D 33.54 
144 12D 32.42 144 13D 30.69 144 14D 30.95 
144 12D 32.20 144 13D 29.04 144 14D 31.52 
451 12D 22.35 451 13D 19.28 451 14D 22.22 
451 12D 22.29 451 13D 19.36 451 14D 23.02 
125 12D 28.43 125 13D 28.64 125 14D 27.57 
125 12D 28.21 125 13D 30.58 125 14D 26.66 
 
As can be seen in table B for patient 12, 13 and 14 Cq values as obtained from RT-PCR, as 
can be seen from this table mIR-208a was not detected in these patients. 
 
Table C: Sample 16, 20 and 22 Cq values as obtained by RT-PCR. 
Target Sample Ct Target Sample Ct Target Sample Ct 
U6 16A 32.62 U6 20A 33.26 U6 22A 33.11 
U6 16A 32.80 U6 20A 31.65 U6 22A 32.92 
1 16A 29.36 1 20A 31.33 1 22A 32.12 
1 16A 29.62 1 20A 31.14 1 22A 31.50 
27a 16A 23.64 27a 20A 26.51 27a 22A 24.20 
27a 16A 24.69 27a 20A 26.08 27a 22A 25.29 
133a 16A 27.22 133a 20A 30.40 133a 22A 29.32 
133a 16A 27.65 133a 20A 31.06 133a 22A 29.84 
133b 16A 36.80 133b 20A 35.70 133b 22A 35.98 
133b 16A 33.66 133b 20A 35.79 133b 22A 33.69 
29b 16A 31.45 29b 20A 35.09 29b 22A 32.90 
29b 16A 32.17 29b 20A 36.08 29b 22A 36.23 
30a 16A 26.38 30a 20A 24.76 30a 22A 27.52 
30a 16A 25.78 30a 20A 23.94 30a 22A 24.33 
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208a 16A   208a 20A   208a 22A 38.44 
208a 16A 39.15 208a 20A   208a 22A   
505 16A 33.14 505 20A 31.70 505 22A 32.06 
505 16A 33.73 505 20A 32.69 505 22A 32.46 
144 16A 33.96 144 20A 33.50 144 22A 34.47 
144 16A 34.58 144 20A 36.11 144 22A 34.46 
451 16A 20.25 451 20A 23.73 451 22A 21.76 
451 16A 21.00 451 20A 23.11 451 22A 26.75 
125 16A 24.74 125 20A 26.91 125 22A 26.73 
125 16A 25.63 125 20A 27.26 125 22A 27.16 
U6 16B 26.80 U6 20B 33.00 U6 22B 29.26 
U6 16B 26.48 U6 20B 31.10 U6 22B 28.87 
1 16B 30.81 1 20B 31.84 1 22B 32.61 
1 16B 30.91 1 20B 31.15 1 22B 32.48 
27a 16B 28.38 27a 20B 25.18 27a 22B 24.84 
27a 16B 27.65 27a 20B 26.05 27a 22B 25.32 
133a 16B 31.19 133a 20B 30.40 133a 22B 30.69 
133a 16B 29.92 133a 20B 31.04 133a 22B 31.93 
133b 16B   133b 20B 37.75 133b 22B   
133b 16B   133b 20B 35.89 133b 22B   
29b 16B 37.94 29b 20B 32.93 29b 22B 37.93 
29b 16B 36.72 29b 20B 38.80 29b 22B   
30a 16B 25.72 30a 20B 25.71 30a 22B 23.17 
30a 16B 28.73 30a 20B 26.14 30a 22B 22.31 
208a 16B   208a 20B   208a 22B   
208a 16B   208a 20B   208a 22B   
505 16B 33.31 505 20B 33.98 505 22B 31.99 
505 16B 36.40 505 20B 35.74 505 22B 33.43 
144 16B   144 20B 31.79 144 22B 29.81 
144 16B 36.06 144 20B 35.82 144 22B 28.71 
451 16B 24.07 451 20B 23.71 451 22B 18.41 
451 16B 24.42 451 20B 23.83 451 22B 19.26 
125 16B 27.30 125 20B 27.26 125 22B 27.71 
125 16B 29.90 125 20B 27.02 125 22B 28.44 
U6 16C 31.13 U6 20C 25.19 U6 22C 31.53 
U6 16C 31.01 U6 20C 25.32 U6 22C 30.91 
1 16C 29.26 1 20C 31.90 1 22C 33.05 
1 16C 29.43 1 20C 32.36 1 22C 32.75 
27a 16C 27.22 27a 20C 25.31 27a 22C 25.25 
27a 16C 26.40 27a 20C 24.32 27a 22C 26.38 
133a 16C 31.53 133a 20C 30.31 133a 22C 31.07 
133a 16C 28.68 133a 20C 30.65 133a 22C 32.67 
133b 16C 39.64 133b 20C 35.63 133b 22C 39.47 
133b 16C   133b 20C 35.52 133b 22C   
29b 16C   29b 20C 33.19 29b 22C   
29b 16C   29b 20C   29b 22C 33.66 
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30a 16C 28.49 30a 20C 24.77 30a 22C 25.26 
30a 16C 27.02 30a 20C 23.79 30a 22C 25.71 
208a 16C   208a 20C   208a 22C   
208a 16C   208a 20C   208a 22C   
505 16C 37.34 505 20C 33.60 505 22C 32.67 
505 16C 33.77 505 20C 38.25 505 22C 34.15 
144 16C 33.51 144 20C 33.02 144 22C 37.27 
144 16C 38.75 144 20C 28.80 144 22C 36.32 
451 16C 20.11 451 20C 19.73 451 22C 24.29 
451 16C 18.67 451 20C 21.75 451 22C 24.88 
125 16C 25.74 125 20C 26.91 125 22C 26.89 
125 16C 24.30 125 20C 28.22 125 22C 26.90 
U6 16D 33.02 U6 20D 28.69 U6 22D 32.37 
U6 16D 31.74 U6 20D 29.29 U6 22D 32.49 
1 16D 29.19 1 20D 33.45 1 22D 32.52 
1 16D 29.42 1 20D 34.02 1 22D 32.82 
27a 16D 27.09 27a 20D 27.68 27a 22D 26.47 
27a 16D 26.21 27a 20D 28.06 27a 22D 28.27 
133a 16D 29.24 133a 20D 32.87 133a 22D 31.43 
133a 16D 28.20 133a 20D 31.72 133a 22D 30.98 
133b 16D   133b 20D   133b 22D 37.86 
133b 16D 36.51 133b 20D   133b 22D 39.04 
29b 16D 37.49 29b 20D 35.17 29b 22D 36.22 
29b 16D   29b 20D 35.86 29b 22D 37.01 
30a 16D 34.07 30a 20D 30.82 30a 22D 24.77 
30a 16D 28.29 30a 20D 34.35 30a 22D 26.18 
208a 16D   208a 20D   208a 22D   
208a 16D   208a 20D   208a 22D   
505 16D 35.71 505 20D 34.68 505 22D 35.93 
505 16D 33.98 505 20D 34.38 505 22D 31.58 
144 16D 37.10 144 20D 33.83 144 22D 37.02 
144 16D 38.49 144 20D 38.23 144 22D 39.86 
451 16D 24.65 451 20D 24.20 451 22D 26.11 
451 16D 27.81 451 20D 22.11 451 22D 25.07 
125 16D 25.64 125 20D 29.12 125 22D 30.55 
125 16D 26.39 125 20D 29.46 125 22D 27.64 
 
 
As can be seen in table c for Sample 16, 20 and 22 Cq values as obtained by RT-PCR, as 
can beseen from this table mIR-208a could not be detected in any of these samples. 
 
 
Table D: Patient 23, 26 and 29 Ct values as obtained by RT PCR 
Target Sample Ct Target Sample Ct Target Sample Ct 
U6 23A 33.29 U6 26A 31.56 U6 29A 31.04 
U6 23A 33.58 U6 26A 33.52 U6 29A 29.81 
1 23A 31.57 1 26A 33.33 1 29A 31.67 
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1 23A 32.14 1 26A 33.93 1 29A 32.53 
27a 23A 25.38 27a 26A 27.19 27a 29A 28.50 
27a 23A 24.89 27a 26A 27.29 27a 29A 26.44 
133a 23A 31.01 133a 26A 31.55 133a 29A 31.42 
133a 23A 29.57 133a 26A 31.75 133a 29A   
133b 23A 32.74 133b 26A 35.26 133b 29A 35.47 
133b 23A 33.43 133b 26A 35.09 133b 29A   
29b 23A 33.57 29b 26A 33.70 29b 29A 35.94 
29b 23A 34.51 29b 26A 34.73 29b 29A 35.21 
30a 23A 24.12 30a 26A 25.67 30a 29A 28.33 
30a 23A 24.20 30a 26A 25.45 30a 29A 27.71 
208a 23A   208a 26A   208a 29A   
208a 23A   208a 26A 39.03 208a 29A   
505 23A 31.54 505 26A 34.11 505 29A 32.88 
505 23A 31.73 505 26A 34.26 505 29A 33.16 
144 23A 32.98 144 26A 32.37 144 29A 29.23 
144 23A 32.87 144 26A 32.58 144 29A 29.45 
451 23A 23.08 451 26A 24.70 451 29A 21.30 
451 23A 23.02 451 26A 24.54 451 29A 20.71 
125 23A 26.54 125 26A 30.29 125 29A 26.69 
125 23A 26.79 125 26A 29.31 125 29A 28.25 
U6 23B 34.33 U6 26B 30.49 U6 29B   
U6 23B 33.05 U6 26B 31.11 U6 29B 37.68 
1 23B 32.29 1 26B 34.27 1 29B 28.97 
1 23B 31.78 1 26B 33.85 1 29B 28.49 
27a 23B 26.24 27a 26B 27.26 27a 29B 25.02 
27a 23B 26.36 27a 26B 26.99 27a 29B 25.56 
133a 23B 30.96 133a 26B 30.28 133a 29B 29.29 
133a 23B 34.29 133a 26B 30.69 133a 29B 36.35 
133b 23B 35.54 133b 26B 33.05 133b 29B 38.10 
133b 23B   133b 26B 33.93 133b 29B 38.38 
29b 23B 33.24 29b 26B 32.76 29b 29B 34.17 
29b 23B 33.44 29b 26B 33.30 29b 29B   
30a 23B 33.53 30a 26B 25.53 30a 29B 26.59 
30a 23B 27.62 30a 26B 25.39 30a 29B 24.11 
208a 23B   208a 26B 39.15 208a 29B   
208a 23B   208a 26B   208a 29B   
505 23B 32.29 505 26B 34.10 505 29B 31.01 
505 23B 31.97 505 26B 32.94 505 29B 31.63 
144 23B 32.47 144 26B 30.38 144 29B 32.68 
144 23B   144 26B 30.34 144 29B 32.20 
451 23B 22.39 451 26B 21.98 451 29B 22.78 
451 23B 22.52 451 26B 22.03 451 29B 23.09 
125 23B 26.72 125 26B 28.24 125 29B 25.94 
125 23B 27.29 125 26B 28.43 125 29B 26.93 
U6 23C 33.49 U6 26C 34.26 U6 29C 36.96 
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U6 23C 32.57 U6 26C 33.72 U6 29C 32.38 
1 23C 33.10 1 26C 33.93 1 29C 29.06 
1 23C 33.17 1 26C 33.34 1 29C 29.73 
27a 23C 26.41 27a 26C 28.27 27a 29C 28.13 
133a 23C 30.90 133a 26C 30.44 133a 29C 28.67 
133a 23C 31.94 133a 26C 32.53 133a 29C 27.83 
133b 23C   133b 26C 36.23 133b 29C   
133b 23C 39.06 133b 26C 36.17 133b 29C 33.20 
29b 23C   29b 26C 35.75 29b 29C 36.09 
29b 23C 35.19 29b 26C 35.66 29b 29C 36.25 
30a 23C 35.25 30a 26C 25.94 30a 29C 30.11 
30a 23C   30a 26C 26.28 30a 29C 24.02 
208a 23C   208a 26C   208a 29C   
208a 23C   208a 26C   208a 29C 39.71 
505 23C 32.99 505 26C 32.22 505 29C 30.62 
505 23C 33.59 505 26C 33.61 505 29C 30.97 
144 23C 33.44 144 26C 33.70 144 29C 35.48 
144 23C 37.79 144 26C 33.04 144 29C 35.11 
451 23C 24.74 451 26C 23.75 451 29C 23.50 
451 23C 27.00 451 26C 23.35 451 29C 25.72 
125 23C 27.25 125 26C 27.52 125 29C 26.61 
125 23C 27.42 125 26C 27.47 125 29C 26.44 
U6 23D 32.35 U6 26D 29.12 U6 29D 31.69 
U6 23D 33.27 U6 26D 29.00 U6 29D 30.23 
1 23D 31.90 1 26D 32.38 1 29D 29.59 
1 23D 32.09 1 26D 32.03 1 29D 30.91 
27a 23D 27.01 27a 26D 26.08 27a 29D 30.16 
27a 23D 26.97 27a 26D 26.22 27a 29D   
133a 23D 32.42 133a 26D 29.16 133a 29D 28.36 
133a 23D 34.10 133a 26D 29.85 133a 29D 29.74 
133b 23D 35.41 133b 26D 33.10 133b 29D   
133b 23D 33.53 133b 26D 32.55 133b 29D 37.50 
29b 23D   29b 26D 32.42 29b 29D 37.01 
29b 23D 33.85 29b 26D 32.53 29b 29D 37.62 
30a 23D 25.76 30a 26D 23.00 30a 29D 29.05 
30a 23D 26.77 30a 26D 22.47 30a 29D 28.77 
208a 23D   208a 26D   208a 29D   
208a 23D   208a 26D   208a 29D   
505 23D 31.91 505 26D 31.17 505 29D 32.31 
505 23D 32.93 505 26D 30.99 505 29D 32.99 
144 23D 33.00 144 26D 25.78 144 29D 33.77 
144 23D 34.67 144 26D 25.96 144 29D 35.32 
451 23D 27.56 451 26D 17.99 451 29D 26.10 
451 23D 25.36 451 26D 17.99 451 29D 24.15 
125 23D 30.34 125 26D 27.53 125 29D 28.06 




As can be seen in table D for patient 23, 26 and 29 Ct values as obtained by RT PCR, as 




Table E: Patient 30, 31 and 32 CT values as obtained by RT-PCR.  
 
Target Sample Ct Target Sample Ct Target Sample Ct 
U6 30A 30.97 U6 31A 31.22 U6 32A   
U6 30A 33.28 U6 31A 31.19 U6 32A 33.12 
1 30A 31.74 1 31A 31.81 1 32A 37.58 
1 30A 35.01 1 31A 33.61 1 32A 35.33 
27a 30A 28.04 27a 31A 30.30 27a 32A 30.69 
27a 30A 30.48 27a 31A 31.01 27a 32A 31.30 
133a 30A 33.07 133a 31A 32.49 133a 32A 35.74 
133a 30A 32.88 133a 31A 32.93 133a 32A 34.05 
133b 30A 37.02 133b 31A 34.19 133b 32A 39.89 
133b 30A 37.41 133b 31A 33.40 133b 32A 37.87 
29b 30A 37.20 29b 31A   29b 32A   
29b 30A   29b 31A   29b 32A 38.87 
30a 30A 25.34 30a 31A 26.19 30a 32A 29.48 
30a 30A 25.36 30a 31A 32.64 30a 32A 28.43 
208a 30A   208a 31A   208a 32A   
208a 30A   208a 31A   208a 32A   
505 30A 32.18 505 31A 33.33 505 32A 35.03 
505 30A 32.05 505 31A 32.37 505 32A 34.75 
144 30A 35.52 144 31A 36.75 144 32A   
144 30A 34.65 144 31A 35.50 144 32A   
451 30A 24.16 451 31A 24.33 451 32A 29.12 
451 30A 24.02 451 31A 23.56 451 32A 27.33 
125 30A 27.12 125 31A 34.12 125 32A 29.27 
125 30A 27.62 125 31A 30.16 125 32A 30.04 
U6 30B   U6 31B 31.58 U6 32B 29.84 
U6 30B   U6 31B   U6 32B   
1 30B   1 31B 35.81 1 32B 33.95 
1 30B 39.09 1 31B 35.42 1 32B 33.86 
27a 30B 30.86 27a 31B 28.36 27a 32B 29.76 
27a 30B 32.23 27a 31B 28.73 27a 32B 28.68 
133a 30B 34.33 133a 31B 31.49 133a 32B 33.28 
133a 30B 34.72 133a 31B 32.71 133a 32B 34.95 
133b 30B   133b 31B 33.81 133b 32B 37.61 
133b 30B   133b 31B 34.60 133b 32B 38.06 
29b 30B 38.27 29b 31B   29b 32B 37.18 
29b 30B   29b 31B 37.43 29b 32B 38.31 
30a 30B 28.03 30a 31B 26.74 30a 32B 26.93 
30a 30B 27.17 30a 31B 27.25 30a 32B 26.49 
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208a 30B   208a 31B   208a 32B   
208a 30B   208a 31B   208a 32B   
505 30B 33.51 505 31B 31.49 505 32B 33.05 
505 30B 33.34 505 31B 32.58 505 32B 32.74 
144 30B 35.18 144 31B 36.31 144 32B 39.33 
144 30B 35.76 144 31B 39.63 144 32B 36.65 
451 30B 23.60 451 31B 23.33 451 32B 25.77 
451 30B 24.97 451 31B 24.40 451 32B 24.70 
125 30B 30.01 125 31B 28.74 125 32B 26.49 
125 30B 31.10 125 31B 25.03 125 32B 27.07 
U6 30C 35.97 U6 31C   U6 32C   
U6 30C 38.05 U6 31C   U6 32C 33.79 
1 30C   1 31C 35.18 1 32C 36.61 
1 30C 38.45 1 31C 34.27 1 32C 34.43 
27a 30C 31.68 27a 31C 28.80 27a 32C 29.89 
27a 30C 31.21 27a 31C 29.16 27a 32C 29.86 
133a 30C 36.11 133a 31C 30.96 133a 32C 36.68 
133a 30C 37.04 133a 31C 33.74 133a 32C 33.86 
133b 30C   133b 31C 34.17 133b 32C 36.51 
133b 30C   133b 31C 37.75 133b 32C 37.62 
29b 30C 38.73 29b 31C 37.41 29b 32C   
29b 30C   29b 31C 36.51 29b 32C   
30a 30C 28.36 30a 31C   30a 32C 26.05 
30a 30C 28.11 30a 31C 27.01 30a 32C 26.29 
208a 30C   208a 31C   208a 32C   
208a 30C   208a 31C   208a 32C   
505 30C 33.05 505 31C 33.11 505 32C 35.77 
505 30C 33.66 505 31C 31.72 505 32C 34.34 
144 30C 33.87 144 31C 35.03 144 32C 37.47 
144 30C 35.02 144 31C 37.49 144 32C 39.43 
451 30C 25.26 451 31C 24.20 451 32C 24.21 
451 30C 24.19 451 31C 25.72 451 32C 24.59 
125 30C 29.97 125 31C 28.17 125 32C 26.68 
125 30C 29.46 125 31C 27.89 125 32C 26.93 
U6 30D 37.93 U6 31D 36.53 U6 32D 30.96 
U6 30D 32.75 U6 31D   U6 32D 34.70 
1 30D 37.81 1 31D 34.35 1 32D 35.02 
1 30D   1 31D 31.97 1 32D 31.14 
27a 30D 29.05 27a 31D 32.39 27a 32D 31.78 
27a 30D 31.10 27a 31D 31.17 27a 32D 28.24 
133a 30D 32.33 133a 31D 33.60 133a 32D 31.78 
133a 30D 33.74 133a 31D 31.84 133a 32D 30.14 
133b 30D 38.49 133b 31D   133b 32D 33.54 
133b 30D   133b 31D 39.69 133b 32D 32.99 
29b 30D   29b 31D   29b 32D 38.68 
29b 30D 37.21 29b 31D 38.18 29b 32D 38.36 
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30a 30D 27.81 30a 31D 28.81 30a 32D 25.92 
30a 30D 28.43 30a 31D 28.78 30a 32D 25.49 
208a 30D   208a 31D   208a 32D 38.60 
208a 30D   208a 31D 39.04 208a 32D   
505 30D 33.52 505 31D 31.50 505 32D 34.57 
505 30D 33.92 505 31D 32.06 505 32D 33.85 
144 30D 35.16 144 31D 36.49 144 32D 35.54 
144 30D 35.15 144 31D 36.65 144 32D 35.26 
451 30D 22.92 451 31D 32.38 451 32D 22.65 
451 30D 24.71 451 31D 25.28 451 32D 23.51 
125 30D 29.39 125 31D 30.45 125 32D 29.09 
125 30D 31.68 125 31D 29.31 125 32D 27.57 
 
As can be seen in table E for patient 30, 31 and 32 CT values as obtained by RT-PCR.  As 
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